<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AVELOXÂ - moxifloxacin hydrochlorideÂ tablet, film coatedÂ </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use AVELOX safely and effectively.  See full prescribing information for AVELOX.AVELOX (moxifloxacin) hydrochloride Tablet, film-coatedAVELOX (moxifloxacin) hydrochloride Injection, solution for IV useInitial U.S. Approval: 1999</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>Boxed Warning section</h1>
<p class="First"></p>
<p><span class="Bold">Fluoroquinolones</span><span class="Bold">, including AVELOX<span class="Sup">Â®</span>, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. <span class="Italics">[</span></span><span class="Bold"><span class="Italics">see</span></span><span class="Bold"><span class="Italics"> Warnings and Precautions (<a href="#ID_991f3830-51e6-4949-9b52-c7f36026a5ac">5.1</a>)].</span></span></p>
<p><span class="Bold">Fluoroquinolones</span><span class="Bold">, including AVELOX, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid AVELOX in patients with known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_ad1b8fbd-4d2e-4b90-90d1-ec3c7a5baae0">5.2</a>)].</span></span></p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-1"></a><p></p>
<h1>MICROBIOLOGY</h1>
<p class="First"></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-2"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX<span class="Bold"><span class="Sup">Â®</span></span> and other antibacterial drugs, AVELOX should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>AVELOX<span class="Bold"><span class="Sup">Â®</span></span> Tablets and IV are indicated for the treatment of adults (â‰¥ 18 years of age) with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible isolates of the designated microorganisms in the conditions listed below <span class="Italics">[see Dosage and Administration (<a href="#ID_812936f2-16f7-4596-8e4b-568878fdff96">2</a>) and Use </span><span class="Italics">In</span><span class="Italics"> Specific Populations (<a href="#ID_5d5f32bf-6a00-4d38-9548-778f68cfa998">8.5</a>)].</span></p>
<p><span class="Bold">Culture and Susceptibility Testing</span></p>
<p>Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and to determine their susceptibility to moxifloxacin <span class="Italics">[see Clinical Pharmacology (<a href="#_Ref">12.4</a>)]</span>. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.</p>
<p>
Â 
</p>
<p></p>
<p>AVELOX is indicated for the treatment of Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> caused by <span class="Italics">StreptococcusÂ </span><span class="Italics">pneumoniae</span><span class="Italics">, </span><span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">influenzae</span>, or<span class="Italics"> MoraxellaÂ </span><span class="Italics">catarrhalis</span><span class="Italics"> [see Clinical Studies (<a href="#ID_d7b92dbe-fb15-4478-9418-ac64a672b4b4">14.4</a>)]</span>.</p>
<p>
Â 
</p>
<p></p>
<p>AVELOX is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> caused by <span class="Italics">StreptococcusÂ </span><span class="Italics">pneumoniae</span><span class="Italics">, </span><span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">influenzae</span><span class="Italics">, </span><span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">parainfluenzae</span><span class="Italics">, </span><span class="Italics">Klebsiella</span><span class="Italics">Â  </span><span class="Italics">pneumoniae</span><span class="Italics">,</span> methicillin-susceptible <span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span><span class="Italics">, </span>or <span class="Italics">MoraxellaÂ </span><span class="Italics">catarrhalis</span><span class="Italics"> [see Clinical Studies (<a href="#ID_102baef2-9bd4-48ba-974d-4c5f7d5dc608">14.1</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>AVELOX is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> caused by <span class="Italics">StreptococcusÂ </span><span class="Italics">pneumoniae</span> (including multi-drug resistant isolates*), <span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">influenzae</span><span class="Italics">, MoraxellaÂ </span><span class="Italics">catarrhalis</span><span class="Italics">, </span>methicillin-susceptible <span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span><span class="Italics">, </span><span class="Italics">Klebsiella</span><span class="Italics">Â </span><span class="Italics">pneumoniae</span><span class="Italics">, MycoplasmaÂ </span><span class="Italics">pneumoniae</span><span class="Italics">, or </span><span class="Italics">Chlamydophila</span><span class="Italics">Â </span><span class="Italics">pneumoniae</span>.</p>
<p>* MDRSP, Multi-drug resistant <span class="Italics">Streptococcus </span><span class="Italics">pneumoniae</span> includes isolates previously known as PRSP (Penicillin-resistant <span class="Italics">S. </span><span class="Italics">pneumoniae</span>), and are isolates resistant to two or more of the following antibiotics: penicillin (<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> [MIC] â‰¥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole <span class="Italics">[see Clinical Studies (<a href="#ID_5e91c302-8f96-4118-8852-ab5329c5d4e0">14.2</a>)]</span>.</p>
<p>
Â 
</p>
<p></p>
<p>AVELOX is indicated for the treatment of Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by methicillin-susceptible <span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span> or <span class="Italics">StreptococcusÂ </span><span class="Italics">pyogenes</span><span class="Italics"> [see Clinical Studies (<a href="#ID_5b1b79c9-b7c2-4c69-952b-0213b95b59ef">14.5</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>AVELOX is indicated for the treatment of Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by methicillin-susceptible <span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span><span class="Italics">, EscherichiaÂ coli, </span><span class="Italics">Klebsiella</span><span class="Italics">Â </span><span class="Italics">pneumoniae</span><span class="Italics">, </span>or <span class="Italics">Enterobacter</span><span class="Italics">Â cloacae</span><span class="Italics">Â  [</span><span class="Italics">see Clinical Studies (<a href="#ID_055e4f5d-49e4-4ffc-bd6f-7fc701523511">14.6</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>AVELOX is indicated for the treatment of Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span> including polymicrobial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> caused by <span class="Italics">EscherichiaÂ coli, </span><span class="Italics">Bacteroides</span><span class="Italics">Â </span><span class="Italics">fragilis</span><span class="Italics">, StreptococcusÂ </span><span class="Italics">anginosus</span><span class="Italics">, StreptococcusÂ </span><span class="Italics">constellatus</span><span class="Italics">, EnterococcusÂ </span><span class="Italics">faecalis</span><span class="Italics">, ProteusÂ mirabilis, ClostridiumÂ </span><span class="Italics">perfringens</span><span class="Italics">, </span><span class="Italics">Bacteroides</span><span class="Italics">Â </span><span class="Italics">thetaiotaomicron</span><span class="Italics">, or </span><span class="Italics">Peptostreptococcus</span>species <span class="Italics">[see Clinical Studies (<a href="#ID_4981c302-e250-4b04-9128-3e85bf596c8e">14.7</a>)]</span>.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-3"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<table>
<col span="1" width="72%">
<col span="1" width="24%">
<col span="1" width="19%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p></td>
<td><p class="First"><span class="Bold">Dose <br>Every 24 hours</span></p></td>
<td><p class="First"><span class="Bold">Duration</span><br><span class="Bold">(days)</span></p></td>
</tr>
<tr>
<td><p class="First">Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> (1.1)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">10</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> (1.2)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> (1.3)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">7-14</p></td>
</tr>
<tr>
<td><p class="First">Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (SSSI) (1.4)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First">Complicated SSSI (1.5)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">7-21</p></td>
</tr>
<tr class="Last">
<td><p class="First">Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span> (1.6)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">5-14 </p></td>
</tr>
</tbody>
</table>
<p>â€¢No dosage adjustment in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (</p>
<p><a href="#ID_94078caa-c9c8-4703-aecf-c16ff4a592f4">8.6</a></p>
<p>, </p>
<p><a href="#ID_150c0167-1efd-4c6b-80b3-df6fcee4c1da">8.7</a></p>
<p>)â€¢AVELOX Tablets: Administer 4 hours before or 8 hours after antacids, sucralfate, multivitamins and other products with multivalent cations. (</p>
<p><a href="#ID_cf0582ae-e5e6-40b8-9497-b72cb140df62">2.2</a></p>
<p>)â€¢AVELOX IV: Slow IV infusion over 60 minutes. Avoid rapid or bolus IV. (</p>
<p><a href="#ID_58dca58f-d1dd-41b4-a29f-2d5cd0668d39">2.3</a></p>
<p>)â€¢Do not mix with other medications in IV bag or in IV line (</p>
<p><a href="#ID_58dca58f-d1dd-41b4-a29f-2d5cd0668d39">2.3</a></p>
<p>) </p>
<p>
Â 
</p>
<p></p>
<p>The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> as described in <span class="Bold">Table 1</span>.</p>
<a name="_RefID0EDMAE"></a><table>
<caption><span>Table 1 Dosage and Duration of Therapy in Adult Patients</span></caption>
<col span="1" width="55%">
<col span="1" width="11%">
<col span="1" width="14%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span><a href="#footnote-1">*</a></p></td>
<td><p class="First"><span class="Bold">Dose<br>Every 24 hours</span></p></td>
<td><p class="First"><span class="Bold">Duration</span><br><span class="Bold">(days) </span></p></td>
</tr>
<tr>
<td><p class="First">Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> (1.1)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">10</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> (1.2)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span></p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">7â€“14</p></td>
</tr>
<tr>
<td><p class="First">Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (SSSI ) (1.4)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First">Complicated SSSI (1.5)</p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">7â€“21</p></td>
</tr>
<tr>
<td><p class="First">Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span> (1.6) </p></td>
<td><p class="First">400 mg</p></td>
<td><p class="First">5â€“14 </p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<p>Intravenous formulation is indicated when it offers a route of administration advantageous to the patient (for example, patient cannot tolerate an oral dosage form). When switching from intravenous to oral formulation, no dosage adjustment is necessary. Patients whose therapy is started with AVELOX IV may be switched to AVELOX Tablets when clinically indicated at the discretion of the physician. </p>
<p>
Â 
</p>
<p></p>
<p>Oral doses of AVELOX should be administered at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron or zinc, including antacids, sucralfate, multivitamins and VIDEX<span class="Sup">Â®</span> (didanosine) chewable/buffered tablets or the pediatric powder for oral solution<span class="Italics"> [see Drug Interactions (<a href="#_Ref">7.1</a>) and Clinical Pharmacology (<a href="#ID_62d1526b-8665-4970-a317-30d6d25ddfbb">12.3</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>AVELOX Tablets can be taken with or without food, drink fluids liberally. </p>
<p>
Â 
</p>
<p></p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p>AVELOX IV should be administered by INTRAVENOUS infusion only. It is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.</p>
<p>AVELOX IV should be administered by intravenous infusion over a period of 60 minutes by direct infusion or through a Y-type intravenous infusion set which may already be in place. Caution: rapid or bolus intravenous infusion must be avoided. </p>
<p>Because only limited data are available on the compatibility of AVELOX intravenous injection with other intravenous substances, additives or other medications should not be added to AVELOX IV or infused simultaneously through the same intravenous line. If the same intravenous line or a Y-type line is used for sequential infusion of other drugs, or if the â€œpiggybackâ€? method of administration is used, the line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> before and after infusion of AVELOX IV with an infusion solution compatible with AVELOX IV as well as with other drug(s) administered via this common line.</p>
<table>
<col span="1" width="45%">
<col span="1" width="54%">
<tbody class="Headless">
<tr class="First"><td><p class="First"><span class="Bold">AVELOX IV is compatible with the following intravenous solutions at ratios from 1:10 to 10:1</span></p></td></tr>
<tr>
<td><p class="First">0.9% Sodium Chloride Injection, USP</p></td>
<td><p class="First">Sterile Water for Injection, USP</p></td>
</tr>
<tr>
<td><p class="First">1M Sodium Chloride Injection</p></td>
<td><p class="First">10% Dextrose for Injection, USP</p></td>
</tr>
<tr class="Last">
<td><p class="First">5% Dextrose Injection, USP</p></td>
<td><p class="First">Lactated Ringerâ€™s for Injection </p></td>
</tr>
</tbody>
</table>
<p>
Â 
</p>
<p></p>
<p>To prepare AVELOX IV injection premix in flexible containers:</p>
<p>1.Close flow control clamp of administration set.2.Remove cover from port at bottom of container.3.Insert piercing pin from an appropriate transfer set (for example, one that does not require excessive force, such as ISO compatible administration set) into port with a gentle twisting motion until pin is firmly seated. </p>
<p><span class="Bold">NOTE:</span> Refer to complete directions that have been provided with the administration set. </p>
<p>
Â 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>Due to the designated pathogens </dd>
</dl>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-4"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First"></p>
<p>â€¢AVELOX Tablets 400 mg moxifloxacin hydrochloride â€¢AVELOX IV 250 mL flexibag containing 400 mg moxifloxacin hydrochloride in sodium chloride injection (</p>
<p><a href="#ID_c3cb02de-60ba-4f6f-9b4e-bf0ab0c8366b">3.2</a></p>
<p>)</p>
<p>
Â 
</p>
<p></p>
<p>â€¢Containing moxifloxacin hydrochloride (equivalent to 400 mg moxifloxacin)â€¢Oblong, dull red film-coated tablets â€¢Imprinted with BAYER on one side and M400 on the other </p>
<p>
Â 
</p>
<p></p>
<p>â€¢Containing 400 mg moxifloxacin in 0.8% saline (moxifloxacin hydrochloride in sodium chloride injection) with pH ranging from 4.1 to 4.6.â€¢Ready-to-use 250 mL latex-free flexibags. No further dilution is necessaryâ€¢Sterile, preservative free, 0.8% sodium chloride aqueous solution of moxifloxacin hydrochloride </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>AVELOX is contraindicated in persons with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to moxifloxacin or any member of the quinolone class of antimicrobial agents.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-6"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<p>â€¢Increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroids, and in patients with kidney, heart or lung transplants. Discontinue if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in a tendon occurs. (</p>
<p><a href="#ID_991f3830-51e6-4949-9b52-c7f36026a5ac">5.1</a></p>
<p>, </p>
<p><a href="#ID_5d5f32bf-6a00-4d38-9548-778f68cfa998">8.5</a></p>
<p>)â€¢Prolongation of the QT interval and isolated cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> has been reported. Avoid use in patients with known prolongation, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and with drugs that prolong the QT interval. (</p>
<p><a href="#ID_2af3a07f-89df-4dcb-8f17-df88db603966">5.3</a></p>
<p>, </p>
<p><a href="#ID_e058c68c-ef7e-4680-8ab4-6f8e02062d14">7.4</a></p>
<p>, </p>
<p><a href="#ID_5d5f32bf-6a00-4d38-9548-778f68cfa998">8.5</a></p>
<p>). Use caution in patients with proarrhythmic conditions such as clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">acute myocardial ischemia</span>. (</p>
<p><a href="#ID_2af3a07f-89df-4dcb-8f17-df88db603966">5.3</a></p>
<p>)â€¢Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, may occur after first or subsequent doses. Discontinue drug use at first sign of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. (</p>
<p><a href="#ID_125cfcb1-371f-4816-b09a-24e61bee16fd">5.4</a></p>
<p>, </p>
<p><a href="#ID_763c40cc-7b6a-4082-8d28-870552e88104">5.5</a></p>
<p>)â€¢Central nervous system (CNS) events including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and rarely suicidal thoughts or acts may occur after first dose. Use caution in patients with known or suspected CNS disorders that may predispose to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. (</p>
<p><a href="#ID_0d5d19be-2dcf-43bf-a80e-86a937e02283">5.6</a></p>
<p>)â€¢Clostridium difficile-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: Evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (</p>
<p><a href="#ID_a3f8e1dc-5491-433a-953f-4f4903b202d8">5.7</a></p>
<p>)â€¢<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>: Discontinue if symptoms occur. (</p>
<p><a href="#ID_ba0c26f6-e4dd-415e-b21c-c095f31b5717">5.8</a></p>
<p>)</p>
<p>
Â 
</p>
<p></p>
<p>Fluoroquinolones, including AVELOX, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This adverse reaction most frequently involves the Achilles tendon, and rupture of the Achilles tendon may require surgical repair. <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites have also been reported. The risk of developing fluoroquinolone-associated <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Factors, in addition to age and corticosteroid use, that may independently increase the risk of <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> include strenuous physical activity, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and previous <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> such as <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> have also occurred in patients taking fluoroquinolones who do not have the above risk factors. <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> can occur during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported. AVELOX should be discontinued if the patient experiences <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or rupture of a tendon. Patients should be advised to rest at the first sign of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Adverse Reactions (<a href="#ID_fd93c086-448e-4a91-8a26-47a67344cca6">6.4</a>) and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>Fluoroquinolones, including AVELOX, have neuromuscular blocking activity and may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Postmarketing serious adverse events, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and requirement for ventilatory support, have been associated with fluoroquinolone use in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid AVELOX in patients with known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">[see Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>AVELOX has been shown to prolong the QT interval of the electrocardiogram in some patients. Following oral dosing with 400 mg of AVELOX the mean (Â± SD) change in QTc from the pre-dose value at the time of maximum drug concentration was 6 msec (Â± 26) (n = 787). Following a course of daily intravenous dosing (400 mg; 1 hour infusion each day) the mean change in QTc from the Day 1 pre-dose value was 10 msec (Â±22) on Day 1 (n=667) and 7 msec (Â± 24) on Day 3 (n = 667). </p>
<p>The drug should be avoided in patients with known prolongation of the QT interval, patients with uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and patients receiving Class IA (for example, quinidine, procainamide) or Class III (for example, amiodarone, sotalol) antiarrhythmic agents, due to the lack of clinical experience with the drug in these patient populations.</p>
<p>Pharmacokinetic studies between AVELOX and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. An additive effect of AVELOX and these drugs cannot be excluded; therefore caution should be exercised when AVELOX is given concurrently with these drugs. In premarketing clinical trials, the rate of cardiovascular adverse events was similar in 798 AVELOX and 702 comparator treated patients who received concomitant therapy with drugs known to prolong the QTc interval.</p>
<p>AVELOX should be used with caution in patients with ongoing proarrhythmic conditions, such as clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">acute myocardial ischemia</span>. The magnitude of QT prolongation may increase with increasing concentrations of the drug or increasing rates of infusion of the intravenous formulation. Therefore the recommended dose or infusion rate should not be exceeded. QT prolongation may lead to an increased risk for <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>. No excess in cardiovascular morbidity or mortality attributable to QTc prolongation occurred with AVELOX treatment in over 15,500 patients in controlled clinical studies, including 759 patients who were hypokalemic at the start of treatment, and there was no increase in mortality in over 18,000 AVELOX tablet treated patients in a postmarketing observational study in which ECGs were not performed. Elderly patients using IV AVELOX may be more susceptible to drug-associated QT prolongation. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Use In Specific Populations, (<a href="#ID_5d5f32bf-6a00-4d38-9548-778f68cfa998">8.5</a>).]</span> In addition, AVELOX should be used with caution in patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span>. <span class="Italics">[See Clinical Pharmacology (<a href="#ID_62d1526b-8665-4970-a317-30d6d25ddfbb">12.3</a>) and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, some following the first dose, have been reported in patients receiving quinolone therapy, including AVELOX. Some reactions were accompanied by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, pharyngeal or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>. Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with epinephrine. AVELOX should be discontinued at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Oxygen, intravenous steroids, and airway management, including intubation, may be administered as indicated.<span class="Italics"> [</span><span class="Italics">see</span><span class="Italics"> Adverse Reactions (<a href="#ID_9a9972a8-3677-4cf4-ad1b-a4e53f325fd0">6</a>) and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>Other serious and sometimes fatal events, some due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, and some due to uncertain etiology, have been reported rarely in patients receiving therapy with quinolones, including AVELOX . These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following:</p>
<p>â€¢<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or severe dermatologic reactions (for example, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>)â€¢<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; serum sicknessâ€¢Allergic pneumonitisâ€¢Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>; <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal insufficiency</span> or failureâ€¢<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>; <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; acute <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> or failureâ€¢<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, including hemolytic and aplastic; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, including <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>; and/or other hematologic abnormalities</p>
<p>The drug should be discontinued immediately at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and supportive measures instituted <span class="Italics">[see Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>) and Adverse Reactions (<a href="#ID_fd93c086-448e-4a91-8a26-47a67344cca6">6.4</a>).</span></p>
<p>
Â 
</p>
<p></p>
<p>Fluoroquinolones, including AVELOX, may cause central nervous system (CNS) events, including: <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span> or <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span> <span class="Italics">[see Adverse Reactions (<a href="#ID_8b973740-5b37-4460-ac8a-512a650f9d9c">6.2</a>, <a href="#ID_fd93c086-448e-4a91-8a26-47a67344cca6">6.4</a>)].</span></p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> (including <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) have been reported in patients receiving fluoroquinolones. Fluoroquinolones may also cause central nervous system (CNS) events including: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and, rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving AVELOX, the drug should be discontinued and appropriate measures instituted. As with all fluoroquinolones, AVELOX should be used with caution in patients with known or suspected CNS disorders (for example, severe <span class="product-label-link" type="condition" conceptid="4278243" conceptname="Cerebral arteriosclerosis">cerebral arteriosclerosis</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>) or in the presence of other risk factors that may predispose to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. <span class="Italics">[See Drug Interactions (<a href="#ID_e058c68c-ef7e-4680-8ab4-6f8e02062d14">7.4</a>) Adverse Reactions (<a href="#ID_8b973740-5b37-4460-ac8a-512a650f9d9c">6.2</a>, <a href="#ID_fd93c086-448e-4a91-8a26-47a67344cca6">6.4</a>) and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p><span class="Italics">Clostridium </span><span class="Italics">difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including AVELOX, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. </span><span class="Italics">difficile</span>.</p>
<p><span class="Italics">C. </span><span class="Italics">difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. </span><span class="Italics">difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. </span><span class="Italics">difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. </span><span class="Italics">difficile</span>, and surgical evaluation should be instituted as clinically indicated <span class="Italics">[see Adverse Reactions (<a href="#ID_8b973740-5b37-4460-ac8a-512a650f9d9c">6.2</a>) and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>Rare cases of sensory or sensorimotor axonal <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> affecting small and/or large axons resulting in <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesias</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesias</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> have been reported in patients receiving quinolones including AVELOX. AVELOX should be discontinued if the patient experiences symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> in order to prevent the development of an irreversible condition<span class="Italics"> [see Adverse Reactions (<a href="#ID_8b973740-5b37-4460-ac8a-512a650f9d9c">6.2</a>, <a href="#ID_fd93c086-448e-4a91-8a26-47a67344cca6">6.4</a>) and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>The oral administration of AVELOX caused lameness in immature dogs. Histopathological examination of the weight-bearing joints of these dogs revealed permanent lesions of the cartilage. Related quinolone-class drugs also produce erosions of cartilage of weight-bearing joints and other signs of <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of various species. <span class="Italics">[See Animal Toxicology and/or Pharmacology (<a href="#_Ref">13.2</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>Moderate to severe <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> reactions, the latter of which may manifest as exaggerated sunburn reactions (for example, burning, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, exudation, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) involving areas exposed to light (typically the face, â€œVâ€? area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of quinolone antibiotics after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> occurs. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Adverse Reactions (<a href="#ID_fd93c086-448e-4a91-8a26-47a67344cca6">6.4</a>) and Pharmacokinetics (<a href="#ID_62d1526b-8665-4970-a317-30d6d25ddfbb">12.3</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>Prescribing AVELOX in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria<span class="Italics"> [see Patient Counseling Information (<a href="#ID_158f7154-1419-4db7-aa36-4c53522f0351">17.1</a>)].</span></p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Most common reactions (â‰¥3%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (6.2)</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or </span><a href="#_Ref">www.fda.gov/medwatch</a></p>
<p>
Â 
</p>
<p></p>
<p>The following serious and otherwise important adverse reactions are discussed in greater detail in the warnings and precautions section of the label:</p>
<p>â€¢Tendinopathy and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon Rupture</span></p>
<p><span class="Italics"> [see Warnings and Precautions (<a href="#ID_991f3830-51e6-4949-9b52-c7f36026a5ac">5.1</a>)]</span></p>
<p>â€¢QT Prolongation </p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_2af3a07f-89df-4dcb-8f17-df88db603966">5.3</a>)]</span></p>
<p>â€¢<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_125cfcb1-371f-4816-b09a-24e61bee16fd">5.4</a>)]</span></p>
<p>â€¢Other Serious and Sometimes Fatal Reactions </p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_0d5d19be-2dcf-43bf-a80e-86a937e02283">5.5</a>)]</span></p>
<p>â€¢Central Nervous System Effects </p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_0d5d19be-2dcf-43bf-a80e-86a937e02283">5.6</a>)]</span></p>
<p>â€¢Clostridium difficile-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_a3f8e1dc-5491-433a-953f-4f4903b202d8">5.7</a>)] </span></p>
<p>â€¢<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span> </p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_ba0c26f6-e4dd-415e-b21c-c095f31b5717">5.8</a>)]</span></p>
<p>â€¢<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span></p>
<p><span class="Italics"> [see Warnings and Precautions (<a href="#ID_15b33f8c-1abd-4c3a-8f35-a8add295130d">5.10</a>)] </span></p>
<p>â€¢Development of Drug Resistant Bacteria</p>
<p><span class="Italics"> [see Warnings and Precautions (<a href="#ID_0cd5d8c6-3d32-4a39-860b-417e2dca2683">5.11</a>)]</span></p>
<p>
Â 
</p>
<p></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to AVELOX in 14981 patients in 71 active controlled Phase II- IV clinical trials in different indications <span class="Italics">[see Indications and Usage (1)]</span>. The population studied had a mean age of 50 years (approximately 73% of the population was &lt;65 years of age), 50% were male, 63% were Caucasian, 12% were Asian and 9% were Black. Patients received AVELOX 400 mg once daily PO, IV, or sequentially (IV followed by PO). Treatment duration was usually 6-10 days, and the mean number of days on therapy was 9 days.</p>
<p>Discontinuation of AVELOX due to adverse events occurred in 5.0% of patients overall, 4.1% of patients treated with 400 mg PO, 3.9% with 400 mg IV and 8.2% with sequential therapy 400 mg PO/IV. The most common adverse events leading to discontinuation with the 400 mg PO doses were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.8%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.5%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.4%). The most common adverse event leading to discontinuation with the 400 mg IV dose was <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (0.5%). The most common adverse events leading to discontinuation with the 400 mg IV/PO sequential dose were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (0.4%).</p>
<p>Adverse reactions occurring in â‰¥1% of AVELOX-treated patients and less common adverse reactions, occurring in 0.1 to &lt;1% of AVELOX-treated patients, are shown in <span class="Bold">Tables 2</span> and <span class="Bold">Table 3</span>, respectively. The most common adverse drug reactions (â‰¥3%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<a name="_RefID0EVJAG"></a><table>
<caption><span>Table 2 Common (â‰¥ 1.0%) Adverse Reactions Reported in Active-Controlled Clinical Trials with AVELOX</span></caption>
<col span="1" width="56%">
<col span="1" width="37%">
<col span="1" width="15%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">System Organ Class</span></p></td>
<td><p class="First"><span class="Bold">Adverse Reactions</span><a href="#footnote-1">*</a></p></td>
<td>
<p class="First"><span class="Bold">%</span></p>
<p><span class="Bold">(N=14,981)</span></p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Blood and Lymphatic System Disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td><p class="First">1.1</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td><p class="First">6.9</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td><p class="First">6.0</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td><p class="First">2.4</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td><p class="First">1.9</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td><p class="First">1.5</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></p></td>
<td><p class="First">1.1</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td><p class="First">1.0</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td><p class="First">1.1</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Investigations</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased </p></td>
<td><p class="First">1.1</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Metabolism and Nutritional Disorder</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td><p class="First">4.2</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td><p class="First">3.0</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td><p class="First">1.9</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a></p>
<a name="_RefID0EVPAG"></a><table>
<caption><span>Table 3 Less Common (0.1 to &lt;1.0%) Adverse Reactions Reported in Active-Controlled Clinical Trials with AVELOX (N=14,981)</span></caption>
<col span="1" width="56%">
<col span="1" width="47%">
<tbody class="Headless">
<tr class="First">
<th colspan="1"><span class="Bold">System Organ Class</span></th>
<th colspan="1">
<span class="Bold">Adverse </span><span class="Bold">Reactions<span class="Sup">a</span></span>
</th>
</tr>
<tr>
<td><p class="First"><span class="Bold">Blood and Lymphatic System Disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocythemia</span> </p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> </p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span> </p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Cardiac failure congestive</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span> </p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Ear and Labyrinth Disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux disease</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="442120" conceptname="Injection site extravasation">Infusion site extravasation</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4317968" conceptname="Pain in face">Facial pain</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Hepatobiliary</span><span class="Bold"> disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Hepatic function abnormal</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vulvovaginal candidiasis</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral candidiasis</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Vulvovaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candidiasis</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginal infection</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Oral <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infection</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Investigations</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Gamma-glutamyltransferase increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Blood alkaline phosphatase increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Hepatic enzyme increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">Electrocardiogram QT prolonged</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Blood lactate dehydrogenase increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Platelet count increased</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Blood amylase increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Blood glucose increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Lipase increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin decreased</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Blood creatinine increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Transaminases increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">White blood cell count increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Blood urea increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver function test abnormal</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4216894" conceptname="Precipitous drop in hematocrit">Hematocrit decreased</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">Prothrombin time prolonged</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Eosinophil count increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">Activated partial thromboplastin time</span> prolonged</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Blood bilirubin increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Blood triglycerides increased</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">Blood uric acid increased</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">Blood pressure increased</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Metabolism and Nutrition Disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span> </p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4092930" conceptname="Musculoskeletal chest pain">Musculoskeletal chest pain</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">Tension headache</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">Disorientation</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Renal and Urinary Disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Renal failure acute</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4194652" conceptname="Pruritus of vulva">Vulvovaginal pruritus</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Respiratory, Thoracic, and </span><span class="Bold">Mediastinal</span><span class="Bold"> Disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">Dermatitis allergic</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
</tr>
<tr class="Last">
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>MedDRA Version 12.0</p>
<p>
Â 
</p>
<p></p>
<p>Changes in laboratory parameters, without regard to drug relationship, which are not listed above and which occurred in â‰¥ 2% of patients and at an incidence greater than in controls included: increases in MCH, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, WBCs, PT ratio, <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span>, chloride, albumin, globulin, bilirubin; decreases in hemoglobin, RBCs, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, eosinophils, <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span>, PT ratio, glucose, pO<span class="Sub">2</span>, bilirubin, and amylase. It cannot be determined if any of the above laboratory abnormalities were caused by the drug or the underlying condition being treated.</p>
<p>
Â 
</p>
<p></p>
<p><span class="Bold">Table 4</span> lists adverse reactions that have been identified during post-approval use of AVELOX. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<a name="_RefID0E3IBG"></a><table>
<caption><span>Table 4 Postmarketing Reports of Adverse Drug Reactions</span></caption>
<col span="1" width="53%">
<col span="1" width="47%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">System/Organ Class</span></p></td>
<td><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Blood and Lymphatic System Disorders </span></p></td>
<td>
<p class="First"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></p>
<p><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span></p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_763c40cc-7b6a-4082-8d28-870552e88104">5.5</a>)]</span></p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span> </span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">Ventricular tachyarrhythmias</span> (including in very rare cases <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, and usually in patients with concurrent severe underlying proarrhythmic conditions)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Ear and Labyrinth Disorders</span></p></td>
<td><p class="First">Hearing impairment, including <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span><span class="Underline"> (reversible in majority of cases)</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Vision loss</span> (especially in the course of CNS reactions, transient in majority of cases)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Hepatobiliary</span><span class="Bold"> Disorders </span></p></td>
<td>
<p class="First"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> (predominantly cholestatic)</p>
<p><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> (including fatal cases)</p>
<p><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> </p>
<p>Acute <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> </p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_763c40cc-7b6a-4082-8d28-870552e88104">5.5</a>)]</span></p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span> </span></p></td>
<td>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span></p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> </p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> (including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>)</p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_125cfcb1-371f-4816-b09a-24e61bee16fd">5.4</a>, <a href="#ID_763c40cc-7b6a-4082-8d28-870552e88104">5.5</a>)]</span></p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span> </span></p></td>
<td>
<p class="First"><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> </p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_991f3830-51e6-4949-9b52-c7f36026a5ac">5.1</a>)]</span></p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span></p></td>
<td>
<p class="First">Altered coordination</p>
<p><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span></p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_ba0c26f6-e4dd-415e-b21c-c095f31b5717">5.8</a>)]</span></p>
<p><span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia gravis</span> (exacerbation of)</p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_ad1b8fbd-4d2e-4b90-90d1-ec3c7a5baae0">5.2</a>)]</span></p>
<p><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span></p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span></p>
<p><span class="Italics"><span class="Underline">[see Warnings and Precautions (</span><a href="#ID_ba0c26f6-e4dd-415e-b21c-c095f31b5717">5.8</a><span class="Underline">)]</span></span></p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Psychiatric Disorders </span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reaction</span> (very rarely culminating in self-injurious behavior, such as <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>/thoughts or <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_0d5d19be-2dcf-43bf-a80e-86a937e02283">5.6</a>)]</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Renal and Urinary Disorders </span></p></td>
<td>
<p class="First">Renal dysfunction</p>
<p>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> </p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_763c40cc-7b6a-4082-8d28-870552e88104">5.5</a>)]</span></p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Respiratory, Thoracic and </span><span class="Bold">Mediastinal</span><span class="Bold"> Disorders</span></p></td>
<td>
<p class="First">Allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span></p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_763c40cc-7b6a-4082-8d28-870552e88104">5.5</a>)]</span></p>
</td>
</tr>
<tr class="Last">
<td><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders </span></p></td>
<td>
<p class="First"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> reaction</p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_15b33f8c-1abd-4c3a-8f35-a8add295130d">5.10</a>)]</span></p>
<p><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span></p>
<p><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span></p>
<p><span class="Italics">[see Warnings and Precautions (<a href="#ID_763c40cc-7b6a-4082-8d28-870552e88104">5.5</a>)]</span></p>
</td>
</tr>
</tbody>
</table>
<p>
Â 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>MedDRA Version 12.0</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First"></p>
<table>
<col span="1" width="40%">
<col span="1" width="75%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">Interacting Drug</span></p></td>
<td><p class="First"><span class="Bold">Interaction</span></p></td>
</tr>
<tr>
<td><p class="First">Antacids, sucralfate, multivitamins, and other products containing multivalent cations</p></td>
<td><p class="First">Moxifloxacin absorption is decreased. Administer AVELOX Tablet at least 4 hours before or 8 hours after these products. <a href="#ID_cf0582ae-e5e6-40b8-9497-b72cb140df62">(2.2</a>, <a href="#_Ref">7.1</a>, <a href="#_Ref">12.3</a>, <a href="#ID_0e8db7da-b67f-472f-8890-2110c2ad7c6d">17.2</a>)</p></td>
</tr>
<tr>
<td><p class="First">Warfarin</p></td>
<td><p class="First">Anticoagulant effect of warfarin may be enhanced. Monitor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR, watch for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#ID_fd93c086-448e-4a91-8a26-47a67344cca6">6.4</a>, <a href="#ID_533dc632-54f0-4ba9-90eb-f43098bf5a73">7.2</a>, <a href="#_Ref">12.3</a>)</p></td>
</tr>
<tr class="Last">
<td><p class="First">Class IA and Class III antiarrhythmics:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmic effect</span> may be enhanced. Avoid concomitant use. (<a href="#ID_2af3a07f-89df-4dcb-8f17-df88db603966">5.3</a>, <a href="#ID_e058c68c-ef7e-4680-8ab4-6f8e02062d14">7.4</a>)</p></td>
</tr>
</tbody>
</table>
<p>
Â 
</p>
<p></p>
<p>Quinolones form chelates with alkaline earth and transition metal cations. Oral administration of quinolones with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX<span class="Sup">Â®</span> (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired. Therefore, AVELOX should be taken at least 4 hours before or 8 hours after these agents. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Dosage and Administration (<a href="#ID_cf0582ae-e5e6-40b8-9497-b72cb140df62">2.2</a>), Pharmacokinetics (<a href="#ID_62d1526b-8665-4970-a317-30d6d25ddfbb">12.3</a>), and Patient Counseling Information (<a href="#ID_0e8db7da-b67f-472f-8890-2110c2ad7c6d">17.2</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>Quinolones, including AVELOX, have been reported to enhance the anticoagulant effects of warfarin or its derivatives in the patient population. In addition, infectious disease and its accompanying inflammatory process, age, and general status of the patient are risk factors for increased anticoagulant activity. Therefore the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if a quinolone is administered concomitantly with warfarin or its derivatives.<span class="Italics"> [</span><span class="Italics">see</span><span class="Italics"> Adverse Reactions (<a href="#ID_8b973740-5b37-4460-ac8a-512a650f9d9c">6.2</a>, <a href="#ID_66f1ca50-e599-4ea8-a551-00c800d768d9">6.3</a>), Pharmacokinetics (<a href="#ID_62d1526b-8665-4970-a317-30d6d25ddfbb">12.3</a>), and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>Although not observed with AVELOX in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> <span class="Italics">[see Warnings and Precautions (</span><a href="#ID_0d5d19be-2dcf-43bf-a80e-86a937e02283">5.6</a><span class="Italics">), and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>There is limited information available on the potential for a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> in humans between AVELOX and other drugs that prolong the QTc interval of the electrocardiogram. Sotalol, a Class III antiarrhythmic, has been shown to further increase the QTc interval when combined with high doses of intravenous (IV) AVELOX in dogs. Therefore, AVELOX should be avoided with Class IA and Class III antiarrhythmics. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Warnings and Precautions, (<a href="#ID_2af3a07f-89df-4dcb-8f17-df88db603966">5.3</a>), Nonclinical Toxicology (<a href="#_Ref">13.2</a>), and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>).]</span></p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-9"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<p>â€¢</p>
<p><span class="Bold">Pregnancy:</span></p>
<p> Based on animal data may cause fetal harm (</p>
<p><a href="#ID_910fad12-a608-4fa4-ab3e-4cb0446b0b00">8.1</a></p>
<p>)â€¢</p>
<p><span class="Bold">Geriatrics: </span></p>
<p>Increased risk for severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> further increased by concomitant corticosteroid therapy and increased risk of prolongation of the QT interval. (</p>
<p><a href="#ID_991f3830-51e6-4949-9b52-c7f36026a5ac">5.1</a></p>
<p>, </p>
<p><a href="#ID_ad1b8fbd-4d2e-4b90-90d1-ec3c7a5baae0">5.3</a></p>
<p>, </p>
<p><a href="#ID_5d5f32bf-6a00-4d38-9548-778f68cfa998">8.5</a></p>
<p>)</p>
<p>
Â 
</p>
<p></p>
<p>Because no adequate or well-controlled studies have been conducted in pregnant women, AVELOX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Moxifloxacin was not teratogenic when administered to pregnant rats during organogenesis at oral doses as high as 500 mg/kg/day or 0.24 times the maximum recommended human dose based on systemic exposure (AUC), but decreased fetal body weights and slightly delayed fetal skeletal development (indicative of fetotoxicity) were observed. Intravenous administration of 80 mg/kg/day (approximately 2 times the maximum recommended human dose based on body surface area (mg/m<span class="Sup">2</span>) to pregnant rats resulted in maternal toxicity and a marginal effect on fetal and placental weights and the appearance of the placenta. There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at intravenous doses as high as 80 mg/kg/day. Intravenous administration of 20 mg/kg/day (approximately equal to the maximum recommended human oral dose based upon systemic exposure) to pregnant rabbits during organogenesis resulted in decreased fetal body weights and delayed fetal skeletal ossification. When rib and vertebral malformations were combined, there was an increased fetal and litter incidence of these effects. Signs of maternal toxicity in rabbits at this dose included mortality, abortions, marked reduction of food consumption, decreased water intake, body <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> and <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>. There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> when pregnant cynomolgus monkeys were given oral doses as high as 100 mg/kg/day (2.5 times the maximum recommended human dose based upon systemic exposure). An increased incidence of smaller fetuses was observed at 100 mg/kg/day. In an oral pre- and postnatal development study conducted in rats, effects observed at 500 mg/kg/day included slight increases in duration of pregnancy and prenatal loss, reduced pup birth weight and decreased neonatal survival. Treatment-related maternal mortality occurred during gestation at 500 mg/kg/day in this study.</p>
<p>
Â 
</p>
<p></p>
<p>Moxifloxacin is excreted in the breast milk of rats. Moxifloxacin may also be excreted in human milk. Because of the potential for serious adverse reactions in infants who are nursing from mothers taking AVELOX, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>
Â 
</p>
<p></p>
<p>Safety and effectiveness in pediatric patients and adolescents less than 18 years of age have not been established. AVELOX causes <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in juvenile animals <span class="Italics">[see Boxed Warning, Warnings and Precautions (</span><a href="#ID_8ec28d32-ae57-4482-8418-163c6b076326">5.9</a><span class="Italics">), and Clinical Pharmacology (<a href="#ID_62d1526b-8665-4970-a317-30d6d25ddfbb">12.3</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>Geriatric patients are at increased risk for developing severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> including <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> when being treated with a fluoroquinolone such as AVELOX. This risk is further increased in patients receiving concomitant corticosteroid therapy. <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing AVELOX to elderly patients especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue AVELOX and contact their healthcare provider if any symptoms of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> occur. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Boxed Warning, Warnings and Precautions (<a href="#ID_991f3830-51e6-4949-9b52-c7f36026a5ac">5.1</a>), and Adverse Reactions (<a href="#ID_8b973740-5b37-4460-ac8a-512a650f9d9c">6.2</a>).]</span></p>
<p>In controlled multiple-dose clinical trials, 23% of patients receiving oral AVELOX were greater than or equal to 65 years of age and 9% were greater than or equal to 75 years of age. The clinical trial data demonstrate that there is no difference in the safety and efficacy of oral AVELOX in patients aged 65 or older compared to younger adults. </p>
<p>In trials of intravenous use, 42% of AVELOX patients were greater than or equal to 65 years of age, and 23% were greater than or equal to 75 years of age. The clinical trial data demonstrate that the safety of intravenous AVELOX in patients aged 65 or older was similar to that of comparator-treated patients. In general, elderly patients may be more susceptible to drug-associated effects of the QT interval. Therefore, AVELOX should be avoided in patients taking drugs that can result in prolongation of the QT interval (for example, class IA or class III antiarrhythmics) or in patients with risk factors for <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> (for example, known QT prolongation, uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>). <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Warnings and Precautions (<a href="#ID_2af3a07f-89df-4dcb-8f17-df88db603966">5.3</a>), Drug Interactions (<a href="#ID_e058c68c-ef7e-4680-8ab4-6f8e02062d14">7.4</a>), and Clinical Pharmacology (<a href="#ID_62d1526b-8665-4970-a317-30d6d25ddfbb">12.3</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>The pharmacokinetic parameters of moxifloxacin are not significantly altered in mild, moderate, severe, or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. No dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including those patients requiring hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD) <span class="Italics">[see Dosage and Administration (<a href="#ID_812936f2-16f7-4596-8e4b-568878fdff96">2</a>), and Clinical Pharmacology (<a href="#ID_62d1526b-8665-4970-a317-30d6d25ddfbb">12.3</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>No dosage adjustment is recommended for mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (Child-Pugh Classes A, B, or C). However, due to metabolic disturbances associated with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, which may lead to QT prolongation, AVELOX should be used with caution in these patients <span class="Italics">[see Warnings and Precaution (<a href="#ID_2af3a07f-89df-4dcb-8f17-df88db603966">5.3</a>), and Clinical Pharmacology, (<a href="#ID_62d1526b-8665-4970-a317-30d6d25ddfbb">12.3</a>)].</span></p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>Single oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> up to 2.8 g were not associated with any serious adverse events. In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, the stomach should be emptied and adequate hydration maintained. ECG monitoring is recommended due to the possibility of QT interval prolongation. The patient should be carefully observed and given supportive treatment. The administration of activated charcoal as soon as possible after oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may prevent excessive increase of systemic moxifloxacin exposure. About 3% and 9% of the dose of moxifloxacin, as well as about 2% and 4.5% of its glucuronide metabolite are removed by continuous ambulatory peritoneal dialysis and hemodialysis, respectively.</p>
<p>Single oral AVELOX doses of 2000, 500, and 1500 mg/kg were lethal to rats, mice, and cynomolgus monkeys, respectively. The minimum lethal intravenous dose in mice and rats was 100 mg/kg. Adverse clinical signs included CNS and gastrointestinal effects such as <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>AVELOX (moxifloxacin) hydrochloride is a synthetic broad spectrum antibacterial agent for oral and intravenous administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. It is a slightly yellow to yellow crystalline substance with a molecular weight of 437.9. Its empirical formula is C<span class="Sub">21</span>H<span class="Sub">24</span>FN<span class="Sub">3</span>O<span class="Sub">4</span>*HCl and its chemical structure is as follows:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebe94683-8fd8-4d99-aa13-46ce14dbcd62&amp;name=MM1.jpg"></p>
<p>
Â 
</p>
<p></p>
<p>â€¢AVELOX Tablets are available as film-coated tablets containing moxifloxacin hydrochloride (equivalent to 400 mg moxifloxacin). â€¢The inactive ingredients are microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol and ferric oxide.</p>
<p>
Â 
</p>
<p></p>
<p>â€¢AVELOX IV is available in ready-to-use 250 mL latex-free flexibags as a sterile, preservative free, 0.8% sodium chloride aqueous solution of moxifloxacin hydrochloride (containing 400 mg moxifloxacin) with pH ranging from 4.1 to 4.6.â€¢The appearance of the intravenous solution is yellow. The color does not affect, nor is it indicative of, product stability.â€¢The inactive ingredients are sodium chloride, USP, Water for Injection, USP, and may include hydrochloric acid and/or sodium hydroxide for pH adjustment.â€¢AVELOX IV contains approximately 34.2 mEq (787 mg) of sodium in 250 mL.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>AVELOX is a member of the fluoroquinolone class of antibacterial agents <span class="Italics">[see Microbiology (<a href="#_Ref">12.4</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>Moxifloxacin, given as an oral tablet, is well absorbed from the gastrointestinal tract. The absolute bioavailability of moxifloxacin is approximately 90 percent. Co-administration with a high fat meal (that is, 500 calories from fat) does not affect the absorption of moxifloxacin.</p>
<p>Consumption of 1 cup of yogurt with moxifloxacin does not significantly affect the extent or rate of systemic absorption (AUC).</p>
<a name="_RefID0ELBAI"></a><table>
<caption><span>Table 5 Mean (Â± SD) C<span class="Sub">max</span> and AUC values following single and multiple doses of 400 mg moxifloxacin given orally</span></caption>
<col span="1" width="45%">
<col span="1" width="22%">
<col span="1" width="21%">
<col span="1" width="20%">
<tbody class="Headless">
<tr class="First">
<th colspan="1"></th>
<th colspan="1">
<span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold">(mg/L)</span>
</th>
<th colspan="1">
<span class="Bold">AUC</span><br><span class="Bold">(</span><span class="Bold">mgâ€¢h</span><span class="Bold">/L)</span>
</th>
<th colspan="1">
<span class="Bold">Half-life</span><br><span class="Bold">(</span><span class="Bold">hr</span><span class="Bold">)</span>
</th>
</tr>
<tr>
<td><p class="First">Single Dose Oral<br>   Healthy (n = 372)</p></td>
<td><p class="First">3.1 Â± 1</p></td>
<td><p class="First">36.1 Â± 9.1</p></td>
<td><p class="First">11.5â€“15.6<a href="#footnote-1">*</a></p></td>
</tr>
<tr>
<td><p class="First">Multiple Dose Oral</p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">   Healthy young male/female (n = 15)</p></td>
<td><p class="First">4.5 Â± 0.5</p></td>
<td><p class="First">48 Â± 2.7</p></td>
<td><p class="First">12.7 Â± 1.9</p></td>
</tr>
<tr>
<td><p class="First">   Healthy elderly male (n = 8)</p></td>
<td><p class="First">3.8 Â± 0.3</p></td>
<td><p class="First">51.8 Â± 6.7</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">   Healthy elderly female (n = 8)</p></td>
<td><p class="First">4.6 Â± 0.6</p></td>
<td><p class="First">54.6 Â± 6.7</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">   Healthy young male (n = 8)</p></td>
<td><p class="First">3.6 Â± 0.5</p></td>
<td><p class="First">48.2 Â± 9</p></td>
<td></td>
</tr>
<tr class="Last">
<td><p class="First">   Healthy young female (n = 9)</p></td>
<td><p class="First">4.2 Â± 0.5</p></td>
<td><p class="First">49.3 Â± 9.5</p></td>
<td></td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a></p>
<a name="_RefID0E3FAI"></a><table>
<caption><span>Table 6 Mean (Â± SD) C<span class="Sub">max</span> and AUC values following single and multiple doses of 400 mg moxifloxacin given by 1 hour IV infusion</span></caption>
<col span="1" width="46%">
<col span="1" width="21%">
<col span="1" width="21%">
<col span="1" width="20%">
<tbody class="Headless">
<tr class="First">
<th colspan="1"></th>
<th colspan="1">
<span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold">(mg/L)</span>
</th>
<th colspan="1">
<span class="Bold">AUC</span><br><span class="Bold">(</span><span class="Bold">mgâ€¢h</span><span class="Bold">/L)</span>
</th>
<th colspan="1">
<span class="Bold">Half-life</span><br><span class="Bold">(</span><span class="Bold">hr</span><span class="Bold">)</span>
</th>
</tr>
<tr>
<td><p class="First">Single Dose IV</p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">   Healthy young male/female (n = 56)</p></td>
<td><p class="First">3.9 Â± 0.9</p></td>
<td><p class="First">39.3 Â± 8.6</p></td>
<td><p class="First">8.2 - 15.4<a href="#footnote-2">*</a></p></td>
</tr>
<tr>
<td><p class="First">   Patients (n = 118)</p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">      Male (n = 64)</p></td>
<td><p class="First">4.4 Â± 3.7</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">      Female (n = 54)</p></td>
<td><p class="First">4.5 Â± 2</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">      &lt; 65 years (n = 58)</p></td>
<td><p class="First">4.6 Â± 4.2</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">      â‰¥ 65 years (n = 60)</p></td>
<td><p class="First">4.3 Â± 1.3</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Multiple Dose IV</p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">   Healthy young male (n = 8)</p></td>
<td><p class="First">4.2 Â± 0.8</p></td>
<td><p class="First">38 Â± 4.7</p></td>
<td><p class="First">14.8 Â± 2.2</p></td>
</tr>
<tr>
<td><p class="First">   Healthy elderly (n =12; 8 male, 4 female)</p></td>
<td><p class="First">6.1 Â± 1.3</p></td>
<td><p class="First">48.2 Â± 0.9</p></td>
<td><p class="First">10.1 Â± 1.6</p></td>
</tr>
<tr>
<td><p class="First">   Patients<a href="#footnote-3">â€ </a> (n = 107)</p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">      Male (n = 58)</p></td>
<td><p class="First">4.2 Â± 2.6</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">      Female (n = 49)</p></td>
<td><p class="First">4.6 Â± 1.5</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">      &lt;65 years (n = 52)</p></td>
<td><p class="First">4.1 Â± 1.4</p></td>
<td></td>
<td></td>
</tr>
<tr class="Last">
<td><p class="First">      â‰¥65 years (n = 55)</p></td>
<td><p class="First">4.7 Â± 2.7</p></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-4" href="#footnote-4" class="Sup">4</a></p>
<p><a name="footnote-reference-5" href="#footnote-5" class="Sup">5</a></p>
<p>Plasma concentrations increase proportionately with dose up to the highest dose tested (1200 mg single oral dose). The mean (Â± SD) elimination half-life from plasma is 12 Â± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.</p>
<p>Figure <a href="#_Ref">1</a> Mean Steady-State Plasma Concentrations of Moxifloxacin Obtained With Once Daily Dosing of 400 mg Either Orally (n=10) or by IV Infusion (n=12)</p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebe94683-8fd8-4d99-aa13-46ce14dbcd62&amp;name=MM2.jpg"></p>
<p>
Â 
</p>
<p></p>
<p>Moxifloxacin is approximately 30-50% bound to serum proteins, independent of drug concentration. The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg. Moxifloxacin is widely distributed throughout the body, with tissue concentrations often exceeding plasma concentrations. Moxifloxacin has been detected in the saliva, nasal and bronchial secretions, mucosa of the sinuses, skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid, subcutaneous tissue, skeletal muscle, and abdominal tissues and fluids following oral or intravenous administration of 400 mg. Moxifloxacin concentrations measured post-dose in various tissues and fluids following a 400 mg oral or IV dose are summarized in <span class="Bold">Table 7</span>. The rates of elimination of moxifloxacin from tissues generally parallel the elimination from plasma.</p>
<a name="_RefID0EZOAI"></a><table>
<caption><span>Table 7 Moxifloxacin Concentrations (mean Â± SD) in Tissues and the Corresponding Plasma Concentrations After a Single 400 mg Oral or Intravenous Dose</span></caption>
<col span="1" width="29%">
<col span="1" width="10%">
<col span="1" width="20%">
<col span="1" width="27%">
<col span="1" width="18%">
<tbody class="Headless">
<tr class="First">
<th colspan="1"><span class="Bold">Tissue or Fluid</span></th>
<th colspan="1"><span class="Bold">N</span></th>
<th colspan="1">
<span class="Bold">Plasma</span><br><span class="Bold">Concentration</span><br><span class="Bold">(mcg/mL)</span>
</th>
<th colspan="1">
<span class="Bold">Tissue or Fluid</span><br><span class="Bold">Concentration</span><br><span class="Bold">(mcg/mL or mcg/g)</span>
</th>
<th colspan="1">
<span class="Bold">Tissue</span><br><span class="Bold">Plasma</span><br><span class="Bold">Ratio</span>
</th>
</tr>
<tr><td><p class="First"><span class="Bold">Respiratory</span></p></td></tr>
<tr>
<td><p class="First">Alveolar Macrophages</p></td>
<td><p class="First">5</p></td>
<td><p class="First">3.3 Â± 0.7</p></td>
<td><p class="First">61.8 Â± 27.3</p></td>
<td><p class="First">21.2 Â± 10</p></td>
</tr>
<tr>
<td><p class="First">Bronchial Mucosa</p></td>
<td><p class="First">8</p></td>
<td><p class="First">3.3 Â± 0.7</p></td>
<td><p class="First">5.5 Â± 1.3</p></td>
<td><p class="First">1.7 Â± 0.3</p></td>
</tr>
<tr>
<td><p class="First">Epithelial Lining Fluid</p></td>
<td><p class="First">5</p></td>
<td><p class="First">3.3 Â± 0.7</p></td>
<td><p class="First">24.4 Â± 14.7</p></td>
<td><p class="First">8.7 Â± 6.1</p></td>
</tr>
<tr><td><p class="First"><span class="Bold">Sinus</span></p></td></tr>
<tr>
<td><p class="First">Maxillary Sinus Mucosa</p></td>
<td><p class="First">4</p></td>
<td><p class="First">3.7 Â± 1.1<a href="#footnote-1">*</a></p></td>
<td><p class="First">7.6 Â± 1.7</p></td>
<td><p class="First">2 Â± 0.3</p></td>
</tr>
<tr>
<td><p class="First">Anterior Ethmoid Mucosa</p></td>
<td><p class="First">3</p></td>
<td><p class="First">3.7 Â± 1.1<a href="#footnote-6" class="Sup">6</a></p></td>
<td><p class="First">8.8 Â± 4.3</p></td>
<td><p class="First">2.2 Â± 0.6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">Nasal Polyps</span></p></td>
<td><p class="First">4</p></td>
<td><p class="First">3.7 Â± 1.1<a href="#footnote-6" class="Sup">6</a></p></td>
<td><p class="First">9.8 Â± 4.5</p></td>
<td><p class="First">2.6 Â± 0.6</p></td>
</tr>
<tr><td><p class="First"><span class="Bold">Skin, Musculoskeletal</span></p></td></tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Fluid</p></td>
<td><p class="First">5</p></td>
<td><p class="First">3 Â± 0.5<a href="#footnote-2">â€ </a></p></td>
<td><p class="First">2.6 Â± 0.9</p></td>
<td><p class="First">0.9 Â± 0.2</p></td>
</tr>
<tr>
<td><p class="First">Subcutaneous Tissue</p></td>
<td><p class="First">6</p></td>
<td><p class="First">2.3 Â± 0.4<a href="#footnote-3">â€¡</a></p></td>
<td><p class="First">0.9 Â± 0.3<a href="#footnote-4">Â§</a></p></td>
<td><p class="First">0.4 Â± 0.6</p></td>
</tr>
<tr>
<td><p class="First">Skeletal Muscle</p></td>
<td><p class="First">6</p></td>
<td><p class="First">2.3 Â± 0.4<a href="#footnote-8" class="Sup">8</a></p></td>
<td><p class="First">0.9 Â± 0.2<a href="#footnote-9" class="Sup">9</a></p></td>
<td><p class="First">0.4 Â± 0.1</p></td>
</tr>
<tr><td><p class="First"><span class="Bold">Intra-Abdominal</span></p></td></tr>
<tr>
<td><p class="First">Abdominal tissue</p></td>
<td><p class="First">8</p></td>
<td><p class="First">2.9 Â± 0.5</p></td>
<td><p class="First">7.6 Â± 2</p></td>
<td><p class="First">2.7 Â± 0.8</p></td>
</tr>
<tr>
<td><p class="First">Abdominal exudate</p></td>
<td><p class="First">10</p></td>
<td><p class="First">2.3 Â± 0.5</p></td>
<td><p class="First">3.5 Â±1.2</p></td>
<td><p class="First">1.6 Â± 0.7</p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span> fluid</p></td>
<td><p class="First">6</p></td>
<td><p class="First">2.7 Â± 0.7</p></td>
<td><p class="First">2.3 Â±1.5</p></td>
<td><p class="First">0.8Â±0.4</p></td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-6" href="#footnote-6" class="Sup">6</a></p>
<p><a name="footnote-reference-7" href="#footnote-7" class="Sup">7</a></p>
<p><a name="footnote-reference-8" href="#footnote-8" class="Sup">8</a></p>
<p><a name="footnote-reference-9" href="#footnote-9" class="Sup">9</a></p>
<p>
Â 
</p>
<p></p>
<p>Approximately 52% of an oral or intravenous dose of moxifloxacin is metabolized via glucuronide and sulfate conjugation. The cytochrome P450 system is not involved in moxifloxacin metabolism, and is not affected by moxifloxacin. The sulfate conjugate (M1) accounts for approximately 38% of the dose, and is eliminated primarily in the feces. Approximately 14% of an oral or intravenous dose is converted to a glucuronide conjugate (M2), which is excreted exclusively in the urine. Peak plasma concentrations of M2 are approximately 40% those of the parent drug, while plasma concentrations of M1 are generally less than 10% those of moxifloxacin.</p>
<p><span class="Italics">In vitro</span> studies with cytochrome (CYP) P450 enzymes indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, suggesting that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these enzymes.</p>
<p>
Â 
</p>
<p></p>
<p>Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces). A total of 96% Â± 4% of an oral dose is excreted as either unchanged drug or known metabolites. The mean (Â± SD) apparent total body clearance and renal clearance are 12 Â± 2 L/hr and 2.6 Â± 0.5 L/hr, respectively.</p>
<p>
Â 
</p>
<p></p>
<p>Following oral administration of 400 mg moxifloxacin for 10 days in 16 elderly (8 male; 8 female) and 17 young (8 male; 9 female) healthy volunteers, there were no age-related changes in moxifloxacin pharmacokinetics. In 16 healthy male volunteers (8 young; 8 elderly) given a single 200 mg dose of oral moxifloxacin, the extent of systemic exposure (AUC and C<span class="Sub">max</span>) was not statistically different between young and elderly males and elimination half-life was unchanged. No dosage adjustment is necessary based on age. In large phase III studies, the concentrations around the time of the end of the infusion in elderly patients following intravenous infusion of 400 mg were similar to those observed in young patients. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Use In Specific Populations (<a href="#ID_5d5f32bf-6a00-4d38-9548-778f68cfa998">8.5</a>).]</span></p>
<p>
Â 
</p>
<p></p>
<p>The pharmacokinetics of moxifloxacin in pediatric subjects has not been studied <span class="Italics">[see Use </span><span class="Italics">In</span><span class="Italics"> Specific Populations (<a href="#ID_1833dcd0-9d12-4480-9ece-ba6aa38f5e6d">8.4</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>Following oral administration of 400 mg moxifloxacin daily for 10 days to 23 healthy males (19-75 years) and 24 healthy females (19-70 years), the mean AUC and C<span class="Sub">max</span> were 8% and 16% higher, respectively, in females compared to males. There are no significant differences in moxifloxacin pharmacokinetics between male and female subjects when differences in body weight are taken into consideration.</p>
<p>A 400 mg single dose study was conducted in 18 young males and females. The comparison of moxifloxacin pharmacokinetics in this study (9 young females and 9 young males) showed no differences in AUC or C<span class="Sub">max</span> due to gender. Dosage adjustments based on gender are not necessary.</p>
<p>
Â 
</p>
<p></p>
<p>Steady-state moxifloxacin pharmacokinetics in male Japanese subjects were similar to those determined in Caucasians, with a mean C<span class="Sub">max</span> of 4.1 mcg/mL, an AUC<span class="Sub">24</span> of 47 mcgâ€¢h/mL, and an elimination half-life of 14 hours, following 400 mg p.o. daily.</p>
<p>
Â 
</p>
<p></p>
<p>The pharmacokinetic parameters of moxifloxacin are not significantly altered in mild, moderate, severe, or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. No dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including those patients requiring hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD).</p>
<p>In a single oral dose study of 24 patients with varying degrees of renal function from normal to severely impaired, the mean peak concentrations (C<span class="Sub">max</span>) of moxifloxacin were reduced by 21% and 28% in the patients with moderate (CL<span class="Sub">CR</span>â‰¥ 30 and â‰¤ 60 mL/min) and severe (CL<span class="Sub">CR</span>&lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, respectively. The mean systemic exposure (AUC) in these patients was increased by 13%. In the moderate and severe renally impaired patients, the mean AUC for the sulfate conjugate (M1) increased by 1.7-fold (ranging up to 2.8-fold) and mean AUC and C<span class="Sub">max</span> for the glucuronide conjugate (M2) increased by 2.8-fold (ranging up to 4.8-fold) and 1.4-fold (ranging up to 2.5-fold), respectively. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Use in Specific Populations (<a href="#ID_94078caa-c9c8-4703-aecf-c16ff4a592f4">8.6</a>).]</span></p>
<p>The pharmacokinetics of single dose and multiple dose moxifloxacin were studied in patients with CL<span class="Sub">CR</span>&lt; 20 mL/min on either hemodialysis or continuous ambulatory peritoneal dialysis (8 HD, 8 CAPD). Following a single 400 mg oral dose, the AUC of moxifloxacin in these HD and CAPD patients did not vary significantly from the AUC generally found in healthy volunteers. C<span class="Sub">max</span> values of moxifloxacin were reduced by about 45% and 33% in HD and CAPD patients, respectively, compared to healthy, historical controls. The exposure (AUC) to the sulfate conjugate (M1) increased by 1.4- to 1.5-fold in these patients. The mean AUC of the glucuronide conjugate (M2) increased by a factor of 7.5, whereas the mean C<span class="Sub">max</span> values of the glucuronide conjugate (M2) increased by a factor of 2.5 to 3, compared to healthy subjects. The sulfate and the glucuronide conjugates of moxifloxacin are not microbiologically active, and the clinical implication of increased exposure to these metabolites in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> including those undergoing HD and CAPD has not been studied.</p>
<p>Oral administration of 400 mg QD AVELOX for 7 days to patients on HD or CAPD produced mean systemic exposure (AUC<span class="Sub">ss</span>) to moxifloxacin similar to that generally seen in healthy volunteers. Steady-state C<span class="Sub">max</span> values were about 22% lower in HD patients but were comparable between CAPD patients and healthy volunteers. Both HD and CAPD removed only small amounts of moxifloxacin from the body (approximately 9% by HD, and 3% by CAPD). HD and CAPD also removed about 4% and 2% of the glucuronide metabolite (M2), respectively.</p>
<p>
Â 
</p>
<p></p>
<p>No dosage adjustment is recommended for mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (Child-Pugh Classes A, B, or C). However, due to metabolic disturbances associated with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, which may lead to QT prolongation, AVELOX should be used with caution in these patients <span class="Italics">[see Warnings and Precautions (<a href="#ID_2af3a07f-89df-4dcb-8f17-df88db603966">5.3</a>), Use in Specific Populations (<a href="#ID_150c0167-1efd-4c6b-80b3-df6fcee4c1da">8.7</a>)].</span></p>
<p>In 400 mg single oral dose studies in 6 patients with mild (Child-Pugh Class A) and 10 patients with moderate (Child-Pugh Class B) <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, moxifloxacin mean systemic exposure (AUC) was 78% and 102%, respectively, of 18 healthy controls and mean peak concentration (C<span class="Sub">max</span>)Â was 79% and 84% of controls.</p>
<p>The mean AUC of the sulfate conjugate of moxifloxacin (M1) increased by 3.9-fold (ranging up to 5.9-fold) and 5.7-fold (ranging up to 8-fold) in the mild and moderate groups, respectively. The mean C<span class="Sub">max</span> of M1 increased by approximately 3-fold in both groups (ranging up to 4.7- and 3.9-fold). The mean AUC of the glucuronide conjugate of moxifloxacin (M2) increased by 1.5-fold (ranging up to 2.5-fold) in both groups. The mean C<span class="Sub">max</span> of M2 increased by 1.6- and 1.3-fold (ranging up to 2.7- and 2.1-fold), respectively. The clinical significance of increased exposure to the sulfate and glucuronide conjugates has not been studied. In a subset of patients participating in a clinical trial, the plasma concentrations of moxifloxacin and metabolites determined approximately at the moxifloxacin T<span class="Sub">max</span> following the first intravenous or oral AVELOX dose in the Child-Pugh Class C patients (n=10) were similar to those in the Child-Pugh Class A/B patients (n=5), and also similar to those observed in healthy volunteer studies.</p>
<p>
Â 
</p>
<p></p>
<p>A study of the skin response to ultraviolet (UVA and UVB) and visible radiation conducted in 32 healthy volunteers (8 per group) demonstrated that AVELOX does not show <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> in comparison to placebo. The minimum erythematous dose (MED) was measured before and after treatment with AVELOX (200 mg or 400 mg once daily), lomefloxacin (400 mg once daily), or placebo. In this study, the MED measured for both doses of AVELOX were not significantly different from placebo, while lomefloxacin significantly lowered the MED. </p>
<p>It is difficult to ascribe relative <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> among various fluoroquinolones during actual patient use because other factors play a role in determining a subjectâ€™s susceptibility to this adverse event such as: a patientâ€™s <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">skin pigmentation</span>, frequency and duration of sun and artificial ultraviolet light (UV) exposure, wearing of sunscreen and protective clothing, the use of other concomitant drugs and the dosage and duration of fluoroquinolone therapy <span class="Italics">[see Warnings and Precautions (<a href="#ID_15b33f8c-1abd-4c3a-8f35-a8add295130d">5.10</a>), Adverse Reactions (<a href="#ID_66f1ca50-e599-4ea8-a551-00c800d768d9">6.3</a>), and Patient Counseling Information (<a href="#_RefID_7d199fb8-0870-4eec-84d4-ec385ecaa">17.3</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>The following drug interactions were studied in healthy volunteers or patients. </p>
<p>Antacids and iron significantly reduced bioavailability of moxifloxacin, as observed with other quinolones <span class="Italics">[see Drug Interactions (<a href="#_Ref">7.1</a>)].</span></p>
<p>Calcium, digoxin, itraconazole, morphine, probenecid, ranitidine, theophylline, and warfarin did not significantly affect the pharmacokinetics of moxifloxacin. These results and the data from <span class="Italics">in vitro</span> studies suggest that moxifloxacin is unlikely to significantly alter the metabolic clearance of drugs metabolized by CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 enzymes.</p>
<p>Moxifloxacin had no clinically significant effect on the pharmacokinetics of atenolol, digoxin, glyburide, itraconazole, oral contraceptives, theophylline, and warfarin <span class="Italics">[see Drug Interactions (<a href="#ID_533dc632-54f0-4ba9-90eb-f43098bf5a73">7.2</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>When moxifloxacin (single 400 mg tablet dose) was administered two hours before, concomitantly, or 4 hours after an aluminum/magnesium-containing antacid (900 mg aluminum hydroxide and 600 mg magnesium hydroxide as a single oral dose) to 12 healthy volunteers there was a 26%, 60% and 23% reduction in the mean AUC of moxifloxacin, respectively. Moxifloxacin should be taken at least 4 hours before or 8 hours after antacids containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc, or VIDEX<span class="Sup">Â®</span> (didanosine) chewable/ buffered tablets or the pediatric powder for oral solution. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Dosage and Administration (<a href="#ID_cf0582ae-e5e6-40b8-9497-b72cb140df62">2.2</a>), Drug Interactions (<a href="#_Ref">7.1</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>In a crossover study involving 24 healthy volunteers (12 male; 12 female), the mean atenolol AUC following a single oral dose of 50 mg atenolol with placebo was similar to that observed when atenolol was given concomitantly with a single 400 mg oral dose of moxifloxacin. The mean C<span class="Sub">max</span> of single dose atenolol decreased by about 10% following co-administration with a single dose of moxifloxacin.</p>
<p>
Â 
</p>
<p></p>
<p>Twelve healthy volunteers were administered concomitant moxifloxacin (single 400 mg dose) and calcium (single dose of 500 mg Ca<span class="Sup">++</span> dietary supplement) followed by an additional two doses of calcium 12 and 24 hours after moxifloxacin administration. Calcium had no significant effect on the mean AUC of moxifloxacin. The mean C<span class="Sub">max</span><span class="Sub"></span>was slightly reduced and the time to maximum plasma concentration was prolonged when moxifloxacin was given with calcium compared to when moxifloxacin was given alone (2.5 hours versus 0.9 hours). These differences are not considered to be clinically significant. </p>
<p>
Â 
</p>
<p></p>
<p>No significant effect of moxifloxacin (400 mg once daily for two days) on digoxin (0.6 mg as a single dose) AUC was detected in a study involving 12 healthy volunteers. The mean digoxin C<span class="Sub">max</span><span class="Sub"></span>increased by about 50% during the distribution phase of digoxin. This transient increase in digoxin C<span class="Sub">max</span><span class="Sub"></span>is not viewed to be clinically significant. Moxifloxacin pharmacokinetics were similar in the presence or absence of digoxin. No dosage adjustment for moxifloxacin or digoxin is required when these drugs are administered concomitantly.</p>
<p>
Â 
</p>
<p></p>
<p>In diabetics, glyburide (2.5 mg once daily for two weeks pretreatment and for five days concurrently) mean AUC and C<span class="Sub">max</span><span class="Sub"></span>were 12% and 21% lower, respectively, when taken with moxifloxacin (400 mg once daily for five days) in comparison to placebo. Nonetheless, blood glucose levels were decreased slightly in patients taking glyburide and moxifloxacin in comparison to those taking glyburide alone, suggesting no interference by moxifloxacin on the activity of glyburide. These interaction results are not viewed as clinically significant.</p>
<p>
Â 
</p>
<p></p>
<p>When moxifloxacin tablets were administered concomitantly with iron (ferrous sulfate 100 mg once daily for two days), the mean AUC and C<span class="Sub">max</span> of moxifloxacin was reduced by 39% and 59%, respectively. Moxifloxacin should only be taken more than 4 hours before or 8 hours after iron products. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Dosage and Administration (<a href="#ID_cf0582ae-e5e6-40b8-9497-b72cb140df62">2.2</a>), Drug Interactions (<a href="#_Ref">7.1</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>In a study involving 11 healthy volunteers, there was no significant effect of itraconazole (200 mg once daily for 9 days), a potent inhibitor of cytochrome P4503A4, on the pharmacokinetics of moxifloxacin (a single 400 mg dose given on the 7<span class="Sup">th </span>day of itraconazole dosing). In addition, moxifloxacin was shown not to affect the pharmacokinetics of itraconazole.</p>
<p>
Â 
</p>
<p></p>
<p>No significant effect of morphine sulfate (a single 10 mg intramuscular dose) on the mean AUC and C<span class="Sub">max</span> of moxifloxacin (400 mg single dose) was observed in a study of 20 healthy male and female volunteers.</p>
<p>
Â 
</p>
<p></p>
<p>A placebo-controlled study in 29 healthy female subjects showed that moxifloxacin 400 mg daily for 7 days did not interfere with the hormonal suppression of oral contraception with 0.15 mg levonorgestrel/0.03 mg ethinylestradiol (as measured by serum progesterone, FSH, estradiol, and LH), or with the pharmacokinetics of the administered contraceptive agents.</p>
<p>
Â 
</p>
<p></p>
<p>Probenecid (500 mg twice daily for two days) did not alter the renal clearance and total amount of moxifloxacin (400 mg single dose) excreted renally in a study of 12 healthy volunteers.</p>
<p>
Â 
</p>
<p></p>
<p>No significant effect of ranitidine (150 mg twice daily for three days as pretreatment) on the pharmacokinetics of moxifloxacin (400 mg single dose) was detected in a study involving 10 healthy volunteers.</p>
<p>
Â 
</p>
<p></p>
<p>No significant effect of moxifloxacin (200 mg every twelve hours for 3 days) on the pharmacokinetics of theophylline (400 mg every twelve hours for 3 days) was detected in a study involving 12 healthy volunteers. In addition, theophylline was not shown to affect the pharmacokinetics of moxifloxacin. The effect of co-administration of a 400 mg dose of moxifloxacin with theophylline has not been studied, but it is not expected to be clinically significant based on <span class="Italics">in vitro </span>metabolic data showing that moxifloxacin does not inhibit the CYP1A2 isoenzyme.</p>
<p>
Â 
</p>
<p></p>
<p>No significant effect of moxifloxacin (400 mg once daily for eight days) on the pharmacokinetics of R- and S-warfarin (25 mg single dose of warfarin sodium on the fifth day) was detected in a study involving 24 healthy volunteers. No significant change in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time was observed. <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> Adverse Reactions (<a href="#ID_8b973740-5b37-4460-ac8a-512a650f9d9c">6.2</a>), Drug Interactions (<a href="#ID_533dc632-54f0-4ba9-90eb-f43098bf5a73">7.2</a>)].</span></p>
<p>
Â 
</p>
<p></p>
<p>The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair, and recombination. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C-7 position prevents active efflux, associated with the <span class="Italics">NorA</span> or <span class="Italics">pmrA</span> genes seen in certain Gram-positive bacteria.</p>
<p>
Â 
</p>
<p></p>
<p>The mechanism of action for fluoroquinolones, including moxifloxacin, is different from that of macrolides, beta-lactams, aminoglycosides, or tetracyclines; therefore, microorganisms resistant to these classes of drugs may be susceptible to moxifloxacin. Resistance to fluoroquinolones occurs primarily by a mutation in topoisomerase II (DNA gyrase) or topoisomerase IV genes, decreased outer membrane permeability or drug efflux. <span class="Italics">In vitro</span> resistance to moxifloxacin develops slowly via multiple-step mutations. Resistance to moxifloxacin occurs <span class="Italics">in vitro</span> at a general frequency of between 1.8 x 10<span class="Sup">â€“9</span> to &lt; 1 x 10<span class="Sup">â€“11</span> for Gram-positive bacteria.</p>
<p>
Â 
</p>
<p></p>
<p>Cross-resistance has been observed between moxifloxacin and other fluoroquinolones against Gram-negative bacteria. Gram-positive bacteria resistant to other fluoroquinolones may, however, still be susceptible to moxifloxacin. There is no known cross-resistance between moxifloxacin and other classes of antimicrobials.</p>
<p>Moxifloxacin has been shown to be active against most isolates of the following bacteria, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><span class="Italics">. [</span><span class="Italics">see</span><span class="Italics"> Indications and Usage (<a href="#_Ref">1</a>)].</span></p>
<p><span class="Bold">Gram-positive bacteria</span></p>
<p>â€¢</p>
<p><span class="Italics">EnterococcusÂ </span></p>
<p><span class="Italics">faecalis</span></p>
<p>â€¢</p>
<p><span class="Italics">StaphylococcusÂ </span></p>
<p><span class="Italics">aureus</span></p>
<p>â€¢</p>
<p><span class="Italics">StreptococcusÂ </span></p>
<p><span class="Italics">anginosus</span></p>
<p>â€¢</p>
<p><span class="Italics">StreptococcusÂ </span></p>
<p><span class="Italics">constellatus</span></p>
<p>â€¢</p>
<p><span class="Italics">StreptococcusÂ </span></p>
<p><span class="Italics">pneumoniae</span></p>
<p> (including multi-drug resistant isolates [MDRSP]**)â€¢</p>
<p><span class="Italics">StreptococcusÂ </span></p>
<p><span class="Italics">pyogenes</span></p>
<p>**MDRSP, Multi-drug resistant <span class="Italics">Streptococcus </span><span class="Italics">pneumoniae</span> includes isolates previously known as PRSP (Penicillin-resistant <span class="Italics">S. </span><span class="Italics">pneumoniae</span>), and are isolates resistant to two or more of the following antibiotics: penicillin (MIC) â‰¥2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. </p>
<p><span class="Bold">Gram-negative bacteria</span></p>
<p>â€¢</p>
<p><span class="Italics">Enterobacter</span></p>
<p><span class="Italics">Â cloacae</span></p>
<p>â€¢</p>
<p><span class="Italics">EscherichiaÂ coli</span></p>
<p>â€¢</p>
<p><span class="Italics">Haemophilus</span></p>
<p><span class="Italics">Â </span></p>
<p><span class="Italics">influenzae</span></p>
<p>â€¢</p>
<p><span class="Italics">Haemophilus</span></p>
<p><span class="Italics">Â </span></p>
<p><span class="Italics">parainfluenzae</span></p>
<p>â€¢</p>
<p><span class="Italics">Klebsiella</span></p>
<p><span class="Italics">Â </span></p>
<p><span class="Italics">pneumoniae</span></p>
<p>â€¢</p>
<p><span class="Italics">MoraxellaÂ </span></p>
<p><span class="Italics">catarrhalis</span></p>
<p>â€¢</p>
<p><span class="Italics">ProteusÂ mirabilis</span></p>
<p><span class="Bold">Anaerobic bacteria</span></p>
<p>â€¢</p>
<p><span class="Italics">Bacteroides</span></p>
<p><span class="Italics">Â </span></p>
<p><span class="Italics">fragilis</span></p>
<p>â€¢</p>
<p><span class="Italics">Bacteroides</span></p>
<p><span class="Italics">Â </span></p>
<p><span class="Italics">thetaiotaomicron</span></p>
<p>â€¢</p>
<p><span class="Italics">ClostridiumÂ </span></p>
<p><span class="Italics">perfringens</span></p>
<p>â€¢</p>
<p><span class="Italics">Peptostreptococcus</span></p>
<p><span class="Italics">Â species</span></p>
<p><span class="Bold">Other microorganisms</span></p>
<p>â€¢</p>
<p><span class="Italics">Chlamydophila</span></p>
<p><span class="Italics">Â </span></p>
<p><span class="Italics">pneumoniae</span></p>
<p>â€¢</p>
<p><span class="Italics">MycoplasmaÂ </span></p>
<p><span class="Italics">pneumoniae</span></p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Bold"><span class="Underline">but their clinical significance is unknown</span>. </span>At least 90 percent of the following bacteria exhibit an <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for moxifloxacin. However, the efficacy of AVELOX in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria <span class="Bold">has not been </span>established in adequate and well controlled clinical trials.</p>
<p><span class="Bold">Gram-positive bacteria</span></p>
<p>â€¢</p>
<p><span class="Italics">StaphylococcusÂ </span></p>
<p><span class="Italics">epidermidis</span></p>
<p>â€¢</p>
<p><span class="Italics">StreptococcusÂ </span></p>
<p><span class="Italics">agalactiae</span></p>
<p>â€¢</p>
<p><span class="Italics">StreptococcusÂ </span></p>
<p><span class="Italics">viridans</span></p>
<p><span class="Italics"> group</span></p>
<p><span class="Bold">Gram-negative bacteria</span></p>
<p>â€¢</p>
<p><span class="Italics">Citrobacter</span></p>
<p><span class="Italics">Â </span></p>
<p><span class="Italics">freundii</span></p>
<p>â€¢</p>
<p><span class="Italics">Klebsiellao</span></p>
<p><span class="Italics">Â </span></p>
<p><span class="Italics">xytoca</span></p>
<p>â€¢</p>
<p><span class="Italics">LegionellaÂ </span></p>
<p><span class="Italics">pneumophila</span></p>
<p><span class="Bold">Anaerobic bacteria </span></p>
<p>â€¢</p>
<p><span class="Italics">Fusobacterium</span></p>
<p><span class="Italics">Â species </span></p>
<p>â€¢</p>
<p><span class="Italics">Prevotella</span></p>
<p><span class="Italics">Â species</span></p>
<p>
Â 
</p>
<p></p>
<p>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.</p>
<p>â€¢</p>
<p><span class="Bold">Dilution Techniques</span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth and/or agar).<span class="Sup"> 1</span> The MIC values should be interpreted according to the criteria in Table 8.</p>
<p>â€¢</p>
<p><span class="Bold">Diffusion Techniques</span></p>
<p>Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size prove should be determined using a standardized test method.<span class="Sup">2,3</span> This procedure uses paper disks impregnated with 5 mcg moxifloxacin to test the susceptibility of bacteria to moxifloxacin. The disc diffusion interpretive criteria are provided in Table 8.</p>
<p>â€¢</p>
<p><span class="Bold">Anaerobic Techniques</span></p>
<p>For anaerobic bacteria, the susceptibility to moxifloxacin can be determined by a standardized test method.<span class="Sup">4</span> The MIC values obtained should be interpreted according to the criteria provided in Table 8.</p>
<a name="_RefID0EIXBI"></a><table>
<caption><span>Table 8 Susceptibility Test Interpretive Criteria for Moxifloxacin</span></caption>
<col span="1" width="45%">
<col span="1" width="9%">
<col span="1" width="14%">
<col span="1" width="13%">
<col span="1" width="9%">
<col span="1" width="11%">
<col span="1" width="11%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td><p class="First"><span class="Bold">MIC (mcg/mL)</span></p></td>
<td><p class="First"><span class="Bold">Zone Diameter (mm)</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Species</span></p></td>
<td><p class="First"><span class="Bold">S</span></p></td>
<td><p class="First"><span class="Bold">I</span></p></td>
<td><p class="First"><span class="Bold">R</span></p></td>
<td><p class="First"><span class="Bold">S</span></p></td>
<td><p class="First"><span class="Bold">I</span></p></td>
<td><p class="First"><span class="Bold">R</span></p></td>
</tr>
<tr>
<td><p class="First">Enterobacteriacae </p></td>
<td><p class="First">â‰¤2</p></td>
<td><p class="First">4</p></td>
<td><p class="First">â‰¥8</p></td>
<td><p class="First">â‰¥19</p></td>
<td><p class="First">16â€“18</p></td>
<td><p class="First">â‰¤15</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">EnterococcusÂ </span><span class="Italics">faecalis</span></p></td>
<td><p class="First">â‰¤1</p></td>
<td><p class="First">2</p></td>
<td><p class="First">â‰¥4</p></td>
<td><p class="First">â‰¥18</p></td>
<td><p class="First">15â€“17</p></td>
<td><p class="First">â‰¤14</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span></p></td>
<td><p class="First">â‰¤2</p></td>
<td><p class="First">4</p></td>
<td><p class="First">â‰¥8</p></td>
<td><p class="First">â‰¥19</p></td>
<td><p class="First">16â€“18</p></td>
<td><p class="First">â‰¤15</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">influenzae</span></p></td>
<td><p class="First">â‰¤1</p></td>
<td><p class="First">-<a href="#footnote-1">*</a></p></td>
<td><p class="First">-<a href="#footnote-10" class="Sup">10</a></p></td>
<td><p class="First">â‰¥18</p></td>
<td><p class="First">-<a href="#footnote-10" class="Sup">10</a></p></td>
<td><p class="First">-<a href="#footnote-10" class="Sup">10</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">parainfluenzae</span></p></td>
<td><p class="First">â‰¤1</p></td>
<td><p class="First">-<a href="#footnote-10" class="Sup">10</a></p></td>
<td><p class="First">-<a href="#footnote-10" class="Sup">10</a></p></td>
<td><p class="First">â‰¥18</p></td>
<td><p class="First">-<a href="#footnote-10" class="Sup">10</a></p></td>
<td><p class="First">-<a href="#footnote-10" class="Sup">10</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">StreptococcusÂ </span><span class="Italics">pneumoniae</span></p></td>
<td><p class="First">â‰¤1</p></td>
<td><p class="First">2</p></td>
<td><p class="First">â‰¥4</p></td>
<td><p class="First">â‰¥18</p></td>
<td><p class="First">15â€“17</p></td>
<td><p class="First">â‰¤14<a href="#footnote-2">â€ </a></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">StreptococcusÂ species</span></p></td>
<td><p class="First">â‰¤1</p></td>
<td><p class="First">2</p></td>
<td><p class="First">â‰¥4</p></td>
<td><p class="First">â‰¥18</p></td>
<td><p class="First">15â€“17</p></td>
<td><p class="First">â‰¤14<a href="#footnote-11" class="Sup">11</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">AnaerobicÂ bacteria</span></p></td>
<td><p class="First">â‰¤2</p></td>
<td><p class="First">4</p></td>
<td><p class="First">â‰¥8</p></td>
<td><p class="First">-</p></td>
<td><p class="First">-</p></td>
<td><p class="First">-</p></td>
</tr>
<tr><td><p class="First">S=susceptible, I=Intermediate, and R=resistant.</p></td></tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-10" href="#footnote-10" class="Sup">10</a></p>
<p><a name="footnote-reference-11" href="#footnote-11" class="Sup">11</a></p>
<p>A report of â€œSusceptibleâ€? indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of the drug product can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected.</p>
<p>â€¢</p>
<p><span class="Bold">Quality Control</span></p>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay and the techniques of the individuals performing the test.<span class="Sup">1</span><span class="Sup">,2,3,4</span> Standard moxifloxacin powder should provide the following range of MIC values noted in Table 9. For the diffusion technique using the 5 mcg moxifloxacin disk, the criteria in Table 9 should be achieved.</p>
<a name="_RefID0EFDCI"></a><table>
<caption><span>Table 9 Acceptable Quality Control Ranges for Moxifloxacin</span></caption>
<col span="1" width="30%">
<col span="1" width="22%">
<col span="1" width="24%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span></span></p></td>
<td><p class="First"><span class="Bold">MIC range <br>(mcg/mL)</span></p></td>
<td><p class="First"><span class="Bold">Zone Diameter<br>(mm)</span></p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Italics">EnterococcusÂ </span><span class="Italics">faecalis</span></p>
<p>ATCC 29212</p>
</td>
<td><p class="First">0.06â€“0.5</p></td>
<td><p class="First">-</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Italics">EscherichiaÂ coli </span></p>
<p>ATCC 25922</p>
</td>
<td><p class="First">0.008â€“0.06</p></td>
<td><p class="First">28â€“35</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">influenzae</span></p>
<p>ATCC 49247</p>
</td>
<td><p class="First">0.008â€“0.03</p></td>
<td><p class="First">31â€“39</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span></p>
<p>ATCC29213</p>
</td>
<td><p class="First">0.015â€“0.06</p></td>
<td><p class="First">-</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span></p>
<p>ATCC25923</p>
</td>
<td><p class="First">-</p></td>
<td><p class="First">28â€“35</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Italics">StreptococcusÂ </span><span class="Italics">pneumoniae</span></p>
<p>ATCC 49619</p>
</td>
<td><p class="First">0.06â€“0.25</p></td>
<td><p class="First">25â€“31</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Italics">Bacteroides</span><span class="Italics">Â </span><span class="Italics">fragilis</span></p>
<p>ATCC 25285</p>
</td>
<td><p class="First">0.125â€“0.5</p></td>
<td><p class="First">-</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Italics">Bacteroides</span><span class="Italics">Â </span><span class="Italics">thetaiotaomicron</span></p>
<p>ATCC 29741</p>
</td>
<td><p class="First">1â€“4</p></td>
<td><p class="First">-</p></td>
</tr>
<tr class="Last">
<td>
<p class="First"><span class="Italics">Eubacterium</span><span class="Italics">Â </span><span class="Italics">lentum</span></p>
<p>ATCC 43055</p>
</td>
<td><p class="First">0.125â€“0.5</p></td>
<td><p class="First">-</p></td>
</tr>
</tbody>
</table>
<p>
Â 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd>Range of means from different studies</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">4</a></dt>
<dd>Range of means from different studies</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">5</a></dt>
<dd>Expected C</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">6</a></dt>
<dd>N = 5</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">7</a></dt>
<dd>N = 7</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">8</a></dt>
<dd>N = 12</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">9</a></dt>
<dd>Reflects only non-protein bound concentrations of drug.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">10</a></dt>
<dd>The current absence of data on moxifloxacin-resistant isolates precludes defining any results other than â€œSusceptibleâ€?.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">11</a></dt>
<dd>Isolates yielding test results (MIC or zone diameter) other than susceptible, should be submitted to a reference laboratory for additional testing.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<p>Long term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed.</p>
<p>Moxifloxacin was not mutagenic in 4 bacterial <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> (TA 98, TA 100, TA 1535, TA 1537) used in the Ames <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> reversion assay. As with other quinolones, the positive response observed with moxifloxacin in <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when v79 cells were used. Moxifloxacin was clastogenic in the v79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity <span class="Italics">in vivo</span> in a micronucleus test or a dominant lethal test in mice. </p>
<p>Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 12 times the maximum recommended human dose based on body surface area (mg/m<span class="Sup">2</span>), or at intravenous doses as high as 45 mg/kg/day, approximately equal to the maximum recommended human dose based on body surface area (mg/m<span class="Sup">2</span>). At 500 mg/kg orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.</p>
<p>
Â 
</p>
<p></p>
<p>Quinolones have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals. In studies in juvenile dogs oral doses of moxifloxacin â‰¥ 30 mg/kg/day (approximately 1.5 times the maximum recommended human dose based upon systemic exposure) for 28 days resulted in <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>. There was no evidence of <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in mature monkeys and rats at oral doses up to 135 and 500 mg/kg/day, respectively.</p>
<p>Moxifloxacin at an oral dose of 300 mg/kg did not show an increase in acute toxicity or potential for CNS toxicity (for example, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>) in mice when used in combination with NSAIDs such as diclofenac, ibuprofen, or fenbufen. Some quinolones have been reported to have proconvulsant activity that is exacerbated with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs). </p>
<p>A QT-prolonging effect of moxifloxacin was found in dog studies, at plasma concentrations about five times the human therapeutic level. The combined infusion of sotalol, a Class III antiarrhythmic agent, with moxifloxacin induced a higher degree of QTc prolongation in dogs than that induced by the same dose (30 mg/kg) of moxifloxacin alone. Electrophysiological <span class="Italics">in vitro</span> studies suggested an inhibition of the rapid activating component of the delayed rectifier potassium current (I<span class="Sub">Kr</span>) as an underlying mechanism.</p>
<p>No signs of local intolerability were observed in dogs when moxifloxacin was administered intravenously. After intra-arterial injection, inflammatory changes involving the peri-arterial soft tissue were observed suggesting that intra-arterial administration of AVELOX should be avoided.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p>AVELOX Tablets (400 mg once daily for five days) were evaluated for the treatment of <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">acute bacterial exacerbation of chronic bronchitis</span> in a randomized, double-blind, controlled clinical trial conducted in the US. This study compared AVELOX with clarithromycin (500 mg twice daily for 10 days) and enrolled 629 patients. Clinical success was assessed at 7-17 days post-therapy. The clinical success for AVELOX was 89% (222/250) compared to 89% (224/251) for clarithromycin.</p>
<a name="_RefID0EQLCI"></a><table>
<caption><span>Table 10 Clinical Success Rates at Follow-Up Visit for Clinically Evaluable Patients by Pathogen (<span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span>)</span></caption>
<col span="1" width="32%">
<col span="1" width="28%">
<col span="1" width="30%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">PATHOGEN</span></p></td>
<td><p class="First"><span class="Bold">AVELOX</span></p></td>
<td><p class="First"><span class="Bold">Clarithromycin</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">StreptococcusÂ </span><span class="Italics">pneumoniae</span></p></td>
<td><p class="First">16/16 (100%)</p></td>
<td><p class="First">20/23 (87%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">influenzae</span></p></td>
<td><p class="First">33/37 (89%)</p></td>
<td><p class="First">36/41 (88%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">parainfluenzae</span></p></td>
<td><p class="First">16/16 (100%)</p></td>
<td><p class="First">14/14 (100%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">MoraxellaÂ </span><span class="Italics">catarrhalis</span></p></td>
<td><p class="First">29/34 (85%)</p></td>
<td><p class="First">24/24 (100%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span></p></td>
<td><p class="First">15/16 (94%)</p></td>
<td><p class="First">6/8 (75%)</p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="Italics">Klebsiella</span><span class="Italics">Â </span><span class="Italics">pneumoniae</span></p></td>
<td><p class="First">18/20 (90%)</p></td>
<td><p class="First">10/11 (91%)</p></td>
</tr>
</tbody>
</table>
<p>The microbiological eradication rates (eradication plus presumed eradication) in AVELOX treated patients were <span class="Italics">StreptococcusÂ </span><span class="Italics">pneumoniae</span><span class="Italics">Â </span> 100%, <span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">influenzae</span><span class="Italics">Â </span> 89%, <span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">parainfluenzae</span><span class="Italics">Â </span> 100%, <span class="Italics">MoraxellaÂ </span><span class="Italics">catarrhalis</span><span class="Italics">Â </span>85%, <span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span><span class="Italics">Â </span> 94%, and <span class="Italics">Klebsiella</span><span class="Italics">Â pneumoniaÂ </span> 85%.</p>
<p>
Â 
</p>
<p></p>
<p>A randomized, double-blind, controlled clinical trial was conducted in the US to compare the efficacy of AVELOX Tablets (400 mg once daily) to that of high-dose clarithromycin (500 mg twice daily) in the treatment of patients with clinically and radiologically documented <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">community acquired pneumonia</span>. This study enrolled 474 patients (382 of whom were valid for the efficacy analysis conducted at the 14 - 35 day follow-up visit). Clinical success for clinically evaluable patients was 95% (184/194) for AVELOX and 95% (178/188) for high dose clarithromycin.</p>
<p>A randomized, double-blind, controlled trial was conducted in the US and Canada to compare the efficacy of sequential IV/PO AVELOX 400 mg QD for 7-14 days to an IV/PO fluoroquinolone control (trovafloxacin or levofloxacin) in the treatment of patients with clinically and radiologically documented <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">community acquired pneumonia</span>. This study enrolled 516 patients, 362 of whom were valid for the efficacy analysis conducted at the 7-30 day post-therapy visit. The clinical success rate was 86% (157/182) for AVELOX therapy and 89% (161/180) for the fluoroquinolone comparators. </p>
<p>An open-label ex-US study that enrolled 628 patients compared AVELOX to sequential IV/PO amoxicillin/clavulanate (1.2 g IV q8h/625 mg PO q8h) with or without high-dose IV/PO clarithromycin (500 mg BID). The intravenous formulations of the comparators are not FDA approved. The clinical success rate at Day 5-7 for AVELOX therapy was 93% (241/258) and demonstrated superiority to amoxicillin/clavulanate Â± clarithromycin (85%, 239/280) [95% C.I. of difference in success rates between moxifloxacin and comparator (2.9%, 13.2%)]. The clinical success rate at the 21-28 days post-therapy visit for AVELOX was 84% (216/258), which also demonstrated superiority to the comparators (74%, 208/280) [95% C.I. of difference in success rates between moxifloxacin and comparator (2.6%, 16.3%)].</p>
<p>The clinical success rates by pathogen across four CAP studies are presented in <span class="Bold">Table 11</span>.</p>
<a name="_RefID_CB31A46F_1794_4D6A_B136_1E3D53006"></a><table>
<caption><span>Table 11 Clinical Success Rates By Pathogen (Pooled CAP Studies)</span></caption>
<col span="1" width="36%">
<col span="1" width="14%">
<col span="1" width="15%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">PATHOGEN</span></p></td>
<td><p class="First"><span class="Bold">AVELOX</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">StreptococcusÂ </span><span class="Italics">pneumoniae</span></p></td>
<td><p class="First">80/85</p></td>
<td><p class="First">(94%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span></p></td>
<td><p class="First">17/20</p></td>
<td><p class="First">(85%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Klebsiella</span><span class="Italics">Â </span><span class="Italics">pneumoniae</span></p></td>
<td><p class="First">11/12</p></td>
<td><p class="First">(92%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Haemophilus</span><span class="Italics">Â </span><span class="Italics">influenzae</span></p></td>
<td><p class="First">56/61</p></td>
<td><p class="First">(92%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Chlamydophila</span><span class="Italics">Â </span><span class="Italics">pneumoniae</span></p></td>
<td><p class="First">119/128</p></td>
<td><p class="First">(93%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">MycoplasmaÂ </span><span class="Italics">pneumoniae</span></p></td>
<td><p class="First">73/76</p></td>
<td><p class="First">(96%)</p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="Italics">MoraxellaÂ </span><span class="Italics">catarrhalis</span></p></td>
<td><p class="First">11/12</p></td>
<td><p class="First">(92%)</p></td>
</tr>
</tbody>
</table>
<p>
Â 
</p>
<p></p>
<p>AVELOX was effective in the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">community acquired pneumonia</span> (CAP) caused by multi-drug resistant <span class="Italics">Streptococcus </span><span class="Italics">pneumoniae</span> MDRSP* isolates. Of 37 microbiologically evaluable patients with MDRSP isolates, 35 patients (95%) achieved clinical and bacteriological success post-therapy. The clinical and bacteriological success rates based on the number of patients treated are shown in <span class="Bold">Table 12</span>.</p>
<p>* MDRSP, Multi-drug resistant <span class="Italics">Streptococcus </span><span class="Italics">pneumoniae</span> includes isolates previously known as PRSP (Penicillin-resistant <span class="Italics">S. </span><span class="Italics">pneumoniae</span>), and are isolates resistant to two or more of the following antibiotics: penicillin (MIC â‰¥ 2 mcg/mL), 2<span class="Sup">nd</span> generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.</p>
<a name="_RefID0ETWCI"></a><table>
<caption><span>Table 12 Clinical and Bacteriological Success Rates for AVELOX-Treated MDRSP CAP Patients (Population: Valid for Efficacy)</span></caption>
<col span="1" width="51%">
<col span="1" width="14%">
<col span="1" width="14%">
<col span="1" width="15%">
<col span="1" width="14%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">Screening Susceptibility</span></p></td>
<td><p class="First"><span class="Bold">Clinical Success</span></p></td>
<td><p class="First"><span class="Bold">Bacteriological Success</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">n/N<a href="#footnote-1">*</a></p></td>
<td><p class="First">%</p></td>
<td><p class="First">n/N<a href="#footnote-2">â€ </a></p></td>
<td><p class="First">%</p></td>
</tr>
<tr>
<td><p class="First">Penicillin-resistant</p></td>
<td><p class="First">21/21</p></td>
<td><p class="First">100%<a href="#footnote-3">â€¡</a></p></td>
<td><p class="First">21/21</p></td>
<td><p class="First">100%<a href="#footnote-14" class="Sup">14</a></p></td>
</tr>
<tr>
<td><p class="First">2<span class="Sup">nd</span> generation cephalosporin-resistant </p></td>
<td><p class="First">25/26</p></td>
<td><p class="First">96%<a href="#footnote-14" class="Sup">14</a></p></td>
<td><p class="First">25/26</p></td>
<td><p class="First">96%<a href="#footnote-14" class="Sup">14</a></p></td>
</tr>
<tr>
<td><p class="First">Macrolide-resistant<a href="#footnote-4">Â§</a></p></td>
<td><p class="First">22/23</p></td>
<td><p class="First">96%</p></td>
<td><p class="First">22/23</p></td>
<td><p class="First">96%</p></td>
</tr>
<tr>
<td><p class="First">Trimethoprim/sulfamethoxazole-resistant</p></td>
<td><p class="First">28/30</p></td>
<td><p class="First">93%</p></td>
<td><p class="First">28/30</p></td>
<td><p class="First">93%</p></td>
</tr>
<tr>
<td><p class="First">Tetracycline-resistant</p></td>
<td><p class="First">17/18</p></td>
<td><p class="First">94%</p></td>
<td><p class="First">17/18</p></td>
<td><p class="First">94%</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-12" href="#footnote-12" class="Sup">12</a></p>
<p><a name="footnote-reference-13" href="#footnote-13" class="Sup">13</a></p>
<p><a name="footnote-reference-14" href="#footnote-14" class="Sup">14</a></p>
<p><a name="footnote-reference-15" href="#footnote-15" class="Sup">15</a></p>
<p>Not all isolates were resistant to all antimicrobial classes tested. Success and eradication rates are summarized in Table 13.</p>
<a name="_RefID0EF3CI"></a><table>
<caption><span>Table 13 Clinical Success Rates and Microbiological Eradication Rates for Resistant Streptococcus pneumoniae (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span>)</span></caption>
<col span="1" width="30%">
<col span="1" width="30%">
<col span="1" width="30%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold"><span class="Italics">S. </span></span><span class="Bold"><span class="Italics">pneumoniae</span></span><span class="Bold"> with</span><br><span class="Bold"> MDRSP</span></p></td>
<td><p class="First"><span class="Bold">Clinical Success</span></p></td>
<td><p class="First"><span class="Bold">Bacteriological</span><br><span class="Bold"> Eradication Rate</span></p></td>
</tr>
<tr>
<td><p class="First">Resistant to 2 antimicrobials</p></td>
<td><p class="First">12/13 (92.3 %)</p></td>
<td><p class="First">12/13 (92.3 %)</p></td>
</tr>
<tr>
<td><p class="First">Resistant to 3 antimicrobials </p></td>
<td><p class="First">10/11 (90.9 %)<a href="#footnote-5">*</a></p></td>
<td><p class="First">10/11 (90.9 %)<a href="#footnote-16" class="Sup">16</a></p></td>
</tr>
<tr>
<td><p class="First">Resistant to 4 antimicrobials </p></td>
<td><p class="First">6/6 (100%)</p></td>
<td><p class="First">6/6 (100%)</p></td>
</tr>
<tr>
<td><p class="First">Resistant to 5 antimicrobials</p></td>
<td><p class="First">7/7 (100%)<a href="#footnote-16" class="Sup">16</a></p></td>
<td><p class="First">7/7 (100%)<a href="#footnote-16" class="Sup">16</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span> with MDRSP </p></td>
<td><p class="First">9/9 (100%)</p></td>
<td><p class="First">9/9 (100%)</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-16" href="#footnote-16" class="Sup">16</a></p>
<p>
Â 
</p>
<p></p>
<p>In a controlled double-blind study conducted in the US, AVELOX Tablets (400 mg once daily for ten days) were compared with cefuroxime axetil (250 mg twice daily for ten days) for the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>. The trial included 457 patients valid for the efficacy analysis. Clinical success (cure plus improvement) at the 7 to 21 day post-therapy test of cure visit was 90% for AVELOX and 89% for cefuroxime.</p>
<p>An additional non-comparative study was conducted to gather bacteriological data and to evaluate microbiological eradication in adult patients treated with AVELOX 400 mg once daily for seven days. All patients (n = 336) underwent antral puncture in this study. Clinical success rates and eradication/presumed eradication rates at the 21 to 37 day follow-up visit were 97% (29 out of 30) for <span class="Italics">Streptococcus </span><span class="Italics">pneumoniae</span>, 83% (15 out of 18) for <span class="Italics">Moraxella </span><span class="Italics">catarrhalis</span>, and 80% (24 out of 30) for <span class="Italics">Haemophilus</span><span class="Italics">influenzae</span>.</p>
<p>
Â 
</p>
<p></p>
<p>A randomized, double-blind, controlled clinical trial conducted in the US compared the efficacy of AVELOX 400 mg once daily for seven days with cephalexin HCl 500 mg three times daily for seven days. The percentage of patients treated for uncomplicated <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span> was 30%, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furuncles</span> 8%, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> 16%, <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> 20%, and other <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> 26%. Adjunctive procedures (incision and drainage or debridement) were performed on 17% of the AVELOX treated patients and 14% of the comparator treated patients. Clinical success rates in evaluable patients were 89% (108/122) for AVELOX and 91% (110/121) for cephalexin HCl.</p>
<p>
Â 
</p>
<p></p>
<p>Two randomized, active controlled trials of cSSSI were performed. A double-blind trial was conducted primarily in North America to compare the efficacy of sequential IV/PO AVELOX 400 mg QD for 7-14 days to an IV/PO beta-lactam/beta-lactamase inhibitor control in the treatment of patients with cSSSI. This study enrolled 617 patients, 335 of which were valid for the efficacy analysis. A second open-label International study compared AVELOX 400 mg QD for 7-21 days to sequential IV/PO beta-lactam/beta-lactamase inhibitor control in the treatment of patients with cSSSI. This study enrolled 804 patients, 632 of which were valid for the efficacy analysis. Surgical incision and drainage or debridement was performed on 55% of the AVELOX treated and 53% of the comparator treated patients in these studies and formed an integral part of therapy for this indication. Success rates varied with the type of diagnosis ranging from 61% in patients with infected <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> to 90% in patients with complicated <span class="product-label-link" type="condition" conceptid="138346" conceptname="Erysipelas">erysipelas</span>. These rates were similar to those seen with comparator drugs. The overall success rates in the evaluable patients and the clinical success by pathogen are shown in <span class="Bold">Tables 14 and 15</span>.</p>
<a name="_RefID0E4BDI"></a><table>
<caption><span>Table 14 Overall Clinical Success Rates in Patients with Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></caption>
<col span="1" width="23%">
<col span="1" width="23%">
<col span="1" width="23%">
<col span="1" width="23%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">Study</span></p></td>
<td><p class="First"><span class="Bold">AVELOX </span><br><span class="Bold">n/ N (%)</span></p></td>
<td><p class="First"><span class="Bold">Comparator</span><br><span class="Bold">n/N (%)</span></p></td>
<td><p class="First"><span class="Bold">95% Confidence </span><br><span class="Bold">Interval</span><a href="#footnote-1">*</a></p></td>
</tr>
<tr>
<td><p class="First">North America</p></td>
<td><p class="First">125/162 (77.2%)</p></td>
<td><p class="First">141/173 (81.5%)</p></td>
<td><p class="First">(-14.4%, 2%)</p></td>
</tr>
<tr>
<td><p class="First">International</p></td>
<td><p class="First">254/315 (80.6%)</p></td>
<td><p class="First">268/317 (84.5%)</p></td>
<td><p class="First">(-9.4%, 2.2%)</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-17" href="#footnote-17" class="Sup">17</a></p>
<a name="_RefID_14E47F8A_A756_48AF_9372_2C7041160"></a><table>
<caption><span>Table 15 Clinical Success Rates by Pathogen in Patients with Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></caption>
<col span="1" width="35%">
<col span="1" width="29%">
<col span="1" width="27%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">Pathogen</span></p></td>
<td><p class="First"><span class="Bold">AVELOX </span><br><span class="Bold">n/ N (%)</span></p></td>
<td><p class="First"><span class="Bold">Comparator</span><br><span class="Bold">n/N (%)</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">StaphylococcusÂ </span><span class="Italics">aureus</span><br>(methicillin-susceptible isolates)<a href="#footnote-2">*</a></p></td>
<td><p class="First">106/129 (82.2%)</p></td>
<td><p class="First">120/137 (87.6%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">EscherichiaÂ coli</span></p></td>
<td><p class="First">31/38 (81.6 %)</p></td>
<td><p class="First">28/33 (84.8 %)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Klebsiella</span><span class="Italics">Â </span><span class="Italics">pneumoniae</span></p></td>
<td><p class="First">11/12 (91.7 % )</p></td>
<td><p class="First">7/10 (70%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Enterobacter</span><span class="Italics">Â cloacae</span></p></td>
<td><p class="First">9/11 (81.8%)</p></td>
<td><p class="First">4/7 (57.1%)</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-18" href="#footnote-18" class="Sup">18</a></p>
<p>
Â 
</p>
<p></p>
<p>Two randomized, active controlled trials of cIAI were performed. A double-blind trial was conducted primarily in North America to compare the efficacy of sequential IV/PO AVELOX 400 mg QD for 5-14 days to IV/ piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of patients with cIAI, including <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> with perforation, and <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">bowel perforation</span>. This study enrolled 681 patients, 379 of which were considered clinically evaluable. A second open-label international study compared AVELOX 400 mg QD for 5-14 days to IV ceftriaxone plus IV metronidazole followed by PO amoxicillin/clavulanic acid in the treatment of patients with cIAI. This study enrolled 595 patients, 511 of which were considered clinically evaluable. The clinically evaluable population consisted of subjects with a surgically confirmed complicated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, at least 5 days of treatment and a 25-50 day follow-up assessment for patients at the Test of Cure visit. The overall clinical success rates in the clinically evaluable patients are shown in <span class="Bold">Table 16</span>.</p>
<a name="_RefID0EIIDI"></a><table>
<caption><span>Table 16 Clinical Success Rates in Patients with Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></span></caption>
<col span="1" width="25%">
<col span="1" width="21%">
<col span="1" width="23%">
<col span="1" width="21%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">Study</span></p></td>
<td><p class="First"><span class="Bold">AVELOX </span><br><span class="Bold">n/ N (%)</span></p></td>
<td><p class="First"><span class="Bold">Comparator</span><br><span class="Bold">n/N (%)</span></p></td>
<td><p class="First"><span class="Bold">95% Confidence </span><br><span class="Bold">Interval</span><a href="#footnote-1">*</a></p></td>
</tr>
<tr>
<td><p class="First">North America (overall)</p></td>
<td><p class="First">146/183 (79.8 %)</p></td>
<td><p class="First">153/196 (78.1 %)</p></td>
<td><p class="First">(-7.4%, 9.3%)</p></td>
</tr>
<tr>
<td><p class="First"> Â <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span> </p></td>
<td><p class="First">40/57 (70.2 %)</p></td>
<td><p class="First">49/63 (77.8 %)<a href="#footnote-2">â€ </a></p></td>
<td><p class="First">NA<a href="#footnote-3">â€¡</a></p></td>
</tr>
<tr>
<td><p class="First"> Â Non-<span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span></p></td>
<td><p class="First">106/126 (84.1 %)</p></td>
<td><p class="First">104/133 (78.2 %)</p></td>
<td><p class="First">NA<a href="#footnote-21" class="Sup">21</a></p></td>
</tr>
<tr>
<td><p class="First">International (overall)</p></td>
<td><p class="First">199/246 (80.9 %)</p></td>
<td><p class="First">218/265 (82.3 %)</p></td>
<td><p class="First">(-8.9 %, 4.2%)</p></td>
</tr>
<tr>
<td><p class="First"> Â <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span></p></td>
<td><p class="First">73/93 (78.5 %)</p></td>
<td><p class="First">86/99 (86.9 %)</p></td>
<td><p class="First">NA</p></td>
</tr>
<tr>
<td><p class="First"> Â Non-<span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span></p></td>
<td><p class="First">126/153 (82.4 %)</p></td>
<td><p class="First">132/166 (79.5 %)</p></td>
<td><p class="First">NA</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-19" href="#footnote-19" class="Sup">19</a></p>
<p><a name="footnote-reference-20" href="#footnote-20" class="Sup">20</a></p>
<p><a name="footnote-reference-21" href="#footnote-21" class="Sup">21</a></p>
<p>
Â 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">12</a></dt>
<dd>n = number of patients successfully treated; N = number of patients with MDRSP (from a total of 37 patients)</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">13</a></dt>
<dd>n = number of patients successfully treated (presumed eradication or eradication); N = number of patients with MDRSP (from a total of 37 patients)</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">14</a></dt>
<dd>One patient had a respiratory isolate that was resistant to penicillin and cefuroxime but a blood isolate that was intermediate to penicillin and cefuroxime. The patient is included in the database based on the respiratory isolate.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">15</a></dt>
<dd>Azithromycin, clarithromycin, and erythromycin were the macrolide antimicrobials tested.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">16</a></dt>
<dd>One patient had a respiratory isolate resistant to 5 antimicrobials and a blood isolate resistant to 3 antimicrobials. The patient was included in the category resistant to 5 antimicrobials.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">17</a></dt>
<dd>of difference in success rates between Moxifloxacin and comparator (Moxifloxacin â€“ comparator)</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">18</a></dt>
<dd>methicillin susceptibility was only determined in the North American Study</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">19</a></dt>
<dd>of difference in success rates between AVELOX and comparator (AVELOX â€“ comparator)</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">20</a></dt>
<dd>Excludes 2 patients who required additional surgery within the first 48 hours.</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">21</a></dt>
<dd>NA - not applicable</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-15"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"></p>
<p>1.Clinical and Laboratory Standards Institute (CLSI), Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically 9th edition. Approved Standard CLSI Document M7-A9, CLSI, 950 West Valley Rd., Suite 2500, Wayne, PA  19087, 2012.2.CLSI , Performance Standards for Antimicrobial Susceptibility Testing 22 Informational Supplement. CLSI Document M100-S22, 2012.3.CLSI , </p>
<p><span class="Underline">Performance Standards for Antimicrobial Disk Susceptibility Tests</span></p>
<p> 11th edition. Approved Standard CLSI Document M2-A11, 2012.4.CLSI , </p>
<p><span class="Underline">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria 8<span class="Sup">th</span> edition;</span></p>
<p> Approved Standard CLSI Document M11-A8, 2012</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-16"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>AVELOX (moxifloxacin) hydrochloride tablets are available as oblong, dull red film-coated tablets containing 400 mg moxifloxacin.</p>
<p>The tablet is coded with the word â€œBAYERâ€? on one side and â€œM400â€? on the reverse side. </p>
<table>
<col span="1" width="30%">
<col span="1" width="28%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">Package</span></p></td>
<td><p class="First"><span class="Bold"> NDC Code</span></p></td>
</tr>
<tr>
<td><p class="First">Bottles of 30:</p></td>
<td><p class="First">0085-1733-01</p></td>
</tr>
<tr>
<td><p class="First">Unit Dose Pack of 50:</p></td>
<td><p class="First">0085-1733-02</p></td>
</tr>
<tr class="Last">
<td><p class="First">ABC Pack of 5:</p></td>
<td><p class="First">0085-1733-03</p></td>
</tr>
</tbody>
</table>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15â€“30Â°C (59â€“86Â°F) <span class="Italics">[see USP Controlled Room Temperature]</span>. Avoid high humidity.</p>
<p>
Â 
</p>
<p></p>
<p>AVELOX IV (moxifloxacin) hydrochloride in sodium chloride injection) is available in ready-to-use 250 mL latex-free flexible bags containing 400 mg of moxifloxacin in 0.8% saline. NO FURTHER DILUTION OF THIS PREPARATION IS NECESSARY.</p>
<table>
<col span="1" width="30%">
<col span="1" width="28%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold">Package</span></p></td>
<td><p class="First"><span class="Bold">NDC Code</span></p></td>
</tr>
<tr class="Last">
<td><p class="First">250 mL flexible container</p></td>
<td><p class="First">0085-1737-01</p></td>
</tr>
</tbody>
</table>
<p>Parenteral drug products should be inspected visually for particulate matter prior to administration. Samples containing visible particulates should not be used.</p>
<p>Because the premix flexible containers are for single-use only, any unused portion should be discarded.</p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15â€“30Â°C (59â€“86Â°F) <span class="Italics">[see USP Controlled Room Temperature]</span>.</p>
<p><span class="Bold">DO NOT REFRIGERATE â€“ PRODUCT PRECIPITATES UPON REFRIGERATION. </span></p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-17"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"></p>
<p>See FDA-Approved Medication Guide</p>
<p>
Â 
</p>
<p></p>
<p>Antibacterial drugs including AVELOX should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (for example, the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When AVELOX is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by AVELOX or other antibacterial drugs in the future.</p>
<p>
Â 
</p>
<p></p>
<p>Patients should be informed that AVELOX tablets may be taken with or without food. Patients should be advised to drink fluids liberally.</p>
<p>AVELOX tablets should be taken at least 4 hours before or 8 hours after multivitamins (containing iron or zinc), antacids (containing magnesium or aluminum), sucralfate, or VIDEX<span class="Sup">Â®</span> (didanosine) chewable/buffered tablets or the pediatric powder for oral solution.</p>
<p>
Â 
</p>
<p></p>
<p>To assure safe and effective use of AVELOX, patients should be informed of the following serious adverse reactions that have been associated with AVELOX and other fluoroquinolone use:</p>
<p>â€¢</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">Tendon Disorders</span>:</span></p>
<p> Patients should contact their healthcare provider if they experience <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of a tendon, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or inability to use one of their joints; rest and refrain from exercise; and discontinue AVELOX treatment. The risk of severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorder</span> with fluoroquinolones is higher in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.â€¢</p>
<p><span class="Bold">Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></span></p>
<p>: fluoroquinolones like AVELOX may cause worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> symptoms, including <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and breathing problems. Patients should call their healthcare provider right away if they have any worsening <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or breathing problems.â€¢</p>
<p><span class="Bold">Prolongation of the QT interval:</span></p>
<p> AVELOX may produce changes in the electrocardiogram (QTc interval prolongation). AVELOX should be avoided in patients receiving Class IA (for example quinidine, procainamide) or Class III (for example amiodarone, sotalol) antiarrhythmic agents. AVELOX may add to the QTc prolonging effects of other drugs such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants. The patients should inform their physician of any personal or family history of QTc prolongation or proarrhythmic conditions such as recent <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">acute myocardial ischemia</span>. Patients should contact their physician if they experience <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> spells while taking AVELOX.â€¢</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: </span></p>
<p>Patients should be advised that AVELOX may be associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, even following a single dose. Patients should discontinue AVELOX at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or other signs of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.â€¢</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>:</span></p>
<p> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported in patients receiving quinolones, and they should notify their physician before taking AVELOX if there is a history of this condition. Patients should also inform their physician if they are taking NSAIDs concurrently with AVELOX. â€¢</p>
<p><span class="Bold">Neurologic Adverse Effects (for example, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>): </span></p>
<p>AVELOX may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and vision disorders; therefore, patients should know how they react to this drug before they operate an automobile or machinery or engage in activities requiring mental alertness or coordination.â€¢</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Reaction</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> sometimes resulting in self-injurious behavior have been reported in patients receiving quinolones. Patients should notify their physician if they have a history of psychiatric illness before taking AVELOX.â€¢</p>
<p><span class="Bold">Peripheral Neuropathies:</span></p>
<p> If symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and/or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> develop, patients should discontinue AVELOX and contact their physician.â€¢</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span></span></p>
<p><span class="Bold">:</span></p>
<p> Patients should be informed that <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> has been reported in patients receiving quinolones. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while taking quinolones. If patients need to be outdoors while using quinolones, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. If a sunburn-like reaction or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span> occurs, patients should contact their physician</p>
<p><span class="Italics">.</span></p>
<p>â€¢</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>:</span></p>
<p> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-18"></a><p></p>
<h1>SPL MEDGUIDE</h1>
<p class="First"></p>
<p><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">AVELOX<span class="Sup">Â®</span> (AV-eh-locks</span><span class="Bold">)</span><br><span class="Bold">(</span><span class="Bold">moxifloxacin</span><span class="Bold"> hydrochloride)</span><br><span class="Bold">Tablets</span></p>
<p><span class="Bold">AVELOX<span class="Sup">Â®</span> IV (<span class="Italics">AV-eh-locks</span></span><span class="Bold"><span class="Italics">)</span></span><br><span class="Bold">(</span><span class="Bold">moxifloxacin</span><span class="Bold"> hydrochloride)</span><br><span class="Bold">Injection Solution for IV use</span></p>
<p>Read the Medication Guide that comes with AVELOX<span class="Sup">Â®</span> before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about AVELOX? </span></p>
<p>AVELOX belongs to a class of antibiotics called fluoroquinolones. AVELOX can cause side effects that may be serious or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. If you get any of the following serious side effects, get medical help right away. Talk with your healthcare provider about whether you should continue to take AVELOX. </p>
<p><span class="Bold"> 1. <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tendon (<span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>). </span></p>
<p>â€¢</p>
<p><span class="Bold">Tendon problems can happen in people of all ages who take AVELOX. </span></p>
<p>Tendons are tough cords of tissue that connect muscles to bones. Symptoms of tendon problems may include:âˆ˜<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, tears and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of tendons including the back of the ankle (Achilles), shoulder, hand, or other tendon sites. â€¢</p>
<p><span class="Bold">The risk of getting tendon problems while you take AVELOX is higher if you</span></p>
<p>:âˆ˜Are over 60 years of ageâˆ˜Are taking steroids (corticosteroids)âˆ˜Have had a kidney, heart or lung transplant </p>
<p><span class="Bold">Tendon problems can happen in people who do not have the above risk factors when they take AVELOX.</span></p>
<p>â€¢</p>
<p><span class="Bold">Other reasons that can increase your risk of tendon problems can include: </span></p>
<p>âˆ˜Physical activity or exerciseâˆ˜<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney failure</span> âˆ˜Tendon problems in the past, such as in people with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA)â€¢</p>
<p><span class="Bold">Call your healthcare provider right away at the first sign of <span class="product-label-link" type="condition" conceptid="4068332" conceptname="Tenalgia">tendon pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</span></p>
<p> Stop taking AVELOX until <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> has been ruled out by your healthcare provider. Avoid exercise and using the affected area. The most common area of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> is in the Achilles tendon at the back of your ankle. This can also happen with other tendons. â€¢</p>
<p><span class="Bold">Talk to your healthcare provider about the risk of <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> with continued use of AVELOX.</span></p>
<p> You may need a different antibiotic that is not a fluoroquinolone to treat your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.â€¢</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> can happen while you are taking or after you have finished taking AVELOX. </span></p>
<p><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon ruptures</span> have happened up to several months after patients have finished taking their fluoroquinolone.â€¢</p>
<p><span class="Bold">Get medical help right away if you get any of the following signs or symptoms of a <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>:</span></p>
<p>âˆ˜Hear or feel a snap or pop in a tendon area âˆ˜<span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span> right after an injury in a tendon areaâˆ˜Unable to move the affected area or bear weight </p>
<p><span class="Bold">2. </span><span class="Bold">Worsening</span><span class="Bold"> of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> (a disease which causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>). </span>Fluoroquinolones like AVELOX may cause worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> symptoms, including <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and breathing problems. Call your healthcare provider right away if you have any worsening <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or breathing problems.</p>
<p>See the section â€œ<span class="Bold">What are the possible side effects of AVELOX?</span>â€? for more information about side effects.</p>
<p><span class="Bold"> What is AVELOX? </span></p>
<p>AVELOX is a fluoroquinolone antibiotic medicine used to treat certain types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by certain germs called bacteria in adults 18 years or older. It is not known if AVELOX is safe and works in people under 18 years of age. Children have a higher chance of getting bone, joint, and tendon (musculoskeletal) problems while taking fluoroquinolone antibiotic medicines.</p>
<p>Sometimes <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are caused by viruses rather than by bacteria. Examples include <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> in the sinuses and lungs, such as the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> or flu. Antibiotics, including AVELOX, do not kill viruses.</p>
<p>Call your healthcare provider if you think your condition is not getting better while you are taking AVELOX.</p>
<p><span class="Bold"> Who should not take AVELOX? </span></p>
<p>Do not take AVELOX if you have ever had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to an antibiotic known as a fluoroquinolone, or if you are allergic to any of the ingredients in AVELOX. Ask your healthcare provider if you are not sure. See the list of ingredients in AVELOX at the end of this Medication Guide.</p>
<p><span class="Bold"> What should I tell my healthcare provider before taking AVELOX? </span></p>
<p>See <span class="Bold">â€œWhat is the most important information I should know about AVELOX?â€?</span></p>
<p><span class="Bold"> Tell your healthcare provider about all your medical conditions, including if you: </span></p>
<p>â€¢Have tendon problems â€¢Have a disease that causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>)â€¢Have central nervous system problems (such as <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>)â€¢Have nerve problems â€¢Have or anyone in your family has an irregular heartbeat, especially a condition called â€œQT prolongationâ€? â€¢Have low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>)â€¢Have a slow heartbeat (<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>)â€¢Have a history of seizuresâ€¢Have kidney problemsâ€¢Have <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA) or other history of joint problemsâ€¢Are pregnant or planning to become pregnant. It is not known if AVELOX will harm your unborn child. â€¢Are breast-feeding or planning to breast-feed. It is not known if AVELOX passes into breast milk. You and your healthcare provider should decide whether you will take AVELOX or breast-feed.</p>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins and herbal and dietary supplements. AVELOX and other medicines can affect each other causing side effects. Especially tell your healthcare provider if you take:</p>
<p>â€¢An NSAID (Non-Steroidal Anti-Inflammatory Drug). Many common medicines for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief are NSAIDs. Taking an NSAID while you take AVELOX or other fluoroquinolones may increase your risk of central nervous system effects and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. See â€œ</p>
<p><span class="Bold">What are the possible side effects of AVELOX?</span></p>
<p>â€?â€¢A blood thinner (warfarin, Coumadin, Jantoven).â€¢A medicine to control your heart rate or rhythm (antiarrhythmic) See â€œ</p>
<p><span class="Bold">What are the possible side effects of AVELOX?</span></p>
<p>â€?â€¢An anti-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> medicine.â€¢A tricyclic antidepressant. â€¢Erythromycin.â€¢A water pill (diuretic).â€¢A steroid medicine. Corticosteroids taken by mouth or by injection may increase the chance of <span class="product-label-link" type="condition" conceptid="4344040" conceptname="Tendon injury">tendon injury</span>. See â€œ</p>
<p><span class="Bold">What is the most important information I should know about AVELOX?</span></p>
<p>â€? â€¢Certain medicines may keep AVELOX from working correctly. Take AVELOX either 4 hours before or 8 hours after taking these products: â€¢An antacid, multivitamin, or other product that has magnesium, aluminum, iron, or zincâ€¢Sucralfate (Carafate) â€¢Didanosine (Videx</p>
<p><span class="Sup">Â®</span></p>
<p>, Videx EC</p>
<p><span class="Sup">Â®</span></p>
<p>) </p>
<p><span class="Bold">Ask your healthcare provider if you are not sure if any of your medicines are listed above.</span></p>
<p>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take AVELOX?</span></p>
<p>â€¢</p>
<p><span class="Bold">Take AVELOX once a day exactly as prescribed by your healthcare provider.</span></p>
<p>â€¢</p>
<p><span class="Bold">Take AVELOX at about the same time each day.</span></p>
<p>â€¢</p>
<p><span class="Bold">AVELOX Tablets should be swallowed. </span></p>
<p>â€¢</p>
<p><span class="Bold">AVELOX can be taken with or without food.</span></p>
<p>â€¢</p>
<p><span class="Bold">Drink plenty of fluids while taking AVELOX. </span></p>
<p>â€¢</p>
<p><span class="Bold">AVELOX IV is given to you by intravenous (IV) infusion into your vein slowly, over 60 minutes, as prescribed by your healthcare provider. </span></p>
<p>â€¢</p>
<p><span class="Bold">Do not skip any doses, or stop taking AVELOX even if you begin to feel better, until you finish your prescribed treatment, unless: </span></p>
<p>âˆ˜You have tendon effects (see â€œ</p>
<p><span class="Bold">What is the most important information I should know about AVELOX</span></p>
<p>?â€?). âˆ˜You have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (see â€œ</p>
<p><span class="Bold">What are the possible side effects of AVELOX</span></p>
<p>?â€?), or your healthcare provider tells you to stop. â€¢This will help make sure that all of the bacteria are killed and lower the chance that the bacteria will become resistant to AVELOX. If this happens, AVELOX and other antibiotic medicines may not work in the future. â€¢</p>
<p><span class="Bold">If you miss a dose of AVELOX, take it as soon as you remember. Do not take more than 1 dose of AVELOX in one day. </span></p>
<p>â€¢</p>
<p><span class="Bold">If you take too much, call your healthcare provider or get medical help immediately.</span></p>
<p><span class="Bold"> What should I avoid while taking AVELOX? </span></p>
<p>â€¢AVELOX can make you feel dizzy and lightheaded. Do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how AVELOX affects you. â€¢Avoid sunlamps, tanning beds, and try to limit your time in the sun. AVELOX can make your skin sensitive to the sun (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>) and the light from sunlamps and tanning beds. You could get severe sunburn, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your skin. If you get any of these symptoms while taking AVELOX, call your healthcare provider right away. You should use a sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight. </p>
<p><span class="Bold"> What are the possible side effects of AVELOX?</span></p>
<p>AVELOX can cause side effects that may be serious or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. See â€œ<span class="Bold">What is the most important information I should know about AVELOX?</span>â€? </p>
<p>Other serious side effects of AVELOX include:</p>
<p>â€¢</p>
<p><span class="Bold"> Central Nervous System effectsÂ  </span></p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported in people who take fluoroquinolone antibiotics including AVELOX. Tell your healthcare provider if you have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Ask your healthcare provider whether taking AVELOX will change your risk of having a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. </p>
<p>Central Nervous System (CNS) side effects may happen as soon as after taking the first dose of AVELOX. Talk to your healthcare provider right away if you have any of these side effects, or other changes in mood or behavior:</p>
<p>â€¢Feeling dizzy â€¢<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> â€¢Hear voices, see things, or sense things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>) â€¢Feel <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> â€¢<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremors</span> â€¢Feel anxious or nervous â€¢<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> â€¢<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> â€¢Trouble sleeping â€¢Feel more suspicious (<span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>) â€¢Suicidal thoughts or acts â€¢Nightmaresâ€¢<span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Vision Loss</span> â€¢</p>
<p><span class="Bold"> Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> </span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> can happen in people taking fluoroquinolones, including AVELOX, even after only one dose. Stop taking AVELOX and get emergency medical help right away if you get any of the following symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>: </p>
<p>â€¢<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span> â€¢Trouble breathing or swallowingâ€¢<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of the lips, tongue, faceâ€¢<span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span>, hoarsenessâ€¢Rapid heartbeatâ€¢Faintâ€¢Yellowing of the skin or eyes. Stop taking AVELOX and tell your healthcare provider right away if you get yellowing of your skin or white part of your eyes, or if you have dark urine. These can be signs of a serious reaction to AVELOX (a liver problem).â€¢</p>
<p><span class="Bold"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> </span></p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> may happen in people taking AVELOX even after only one dose. Stop taking AVELOX at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and call your healthcare provider. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> may be a sign of a more serious reaction to AVELOX. </p>
<p>â€¢</p>
<p><span class="Bold">Serious heart rhythm changes</span></p>
<p> (QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>) </p>
<p>Tell your healthcare provider right away if you have a change in your heart beat (a fast or irregular heartbeat), or if you <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>. AVELOX may cause a rare heart problem known as prolongation of the QT interval. This condition can cause an abnormal heartbeat and can be very dangerous. The chances of this event are higher in people: </p>
<p>â€¢Who are elderly â€¢With a family history of prolonged QT interval â€¢With low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>) â€¢Who take certain medicines to control heart rhythm (antiarrhythmics)â€¢</p>
<p><span class="Bold">Intestine <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </span></p>
<p>(<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span>)</p>
<p><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen with most antibiotics, including AVELOX. Call your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not go away, or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>. You may have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen 2 or more months after you have finished your antibiotic. </p>
<p>â€¢</p>
<p><span class="Bold"> Changes in sensation and possible <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> (<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>)</span></p>
<p>Â  </p>
<p>Damage to the nerves in arms, hands, legs, or feet can happen in people taking fluoroquinolones, including AVELOX. Talk with your healthcare provider right away if you get any of the following symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> in your arms, hands, legs, or feet: </p>
<p>â€¢<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> â€¢Burning â€¢Tinglingâ€¢Numbnessâ€¢<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></p>
<p>AVELOX may need to be stopped to prevent permanent <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>. </p>
<p>â€¢</p>
<p><span class="Bold">Sensitivity to sunlight </span></p>
<p>(<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>)</p>
<p>See â€œ<span class="Bold">What should I avoid while taking AVELOX?</span>â€?</p>
<p>The most common side effects of AVELOX include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. </p>
<p>These are not all the possible side effects of AVELOX. Tell your healthcare provider about any side effect that bothers you or that does not go away.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold"> How should I store AVELOX? </span></p>
<p><span class="Bold">AVELOX Tablets</span></p>
<p>â€¢Store AVELOX 59â€“86Â°F (15â€“30Â°C) â€¢Keep AVELOX away from moisture (humidity)</p>
<p><span class="Bold"> Keep AVELOX and all medicines out of the reach of children. </span></p>
<p><span class="Bold"> General Information about AVELOX </span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use AVELOX for a condition for which it is not prescribed. Do not give AVELOX to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about AVELOX. If you would like more information about AVELOX, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about AVELOX that is written for healthcare professionals. For more information go to www.AVELOX.com or call 1-800-526-4099.</p>
<p><span class="Bold"> What are the ingredients in AVELOX? </span></p>
<p>â€¢</p>
<p><span class="Bold"> AVELOX Tablets: </span></p>
<p>âˆ˜Active ingredient: moxifloxacin hydrochlorideâˆ˜Inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol, and ferric oxideâ€¢</p>
<p><span class="Bold"> AVELOX IV:</span></p>
<p>âˆ˜Active ingredient: moxifloxacin hydrochlorideâˆ˜Inactive ingredients: sodium chloride, USP, water for injection, USP, and may include hydrochloric acid and/or sodium hydroxide for pH adjustment</p>
<p>Revised August 2012</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for:<br>Bayer HealthCare Pharmaceuticals Inc.<br>Wayne, NJ 07470</p>
<p>AVELOX Tablets manufactured in Germany<br>AVELOX IV manufactured in Germany <br> or <br>AVELOX IV manufactured in Norway by<br>Fresenius Kabi Norge AS<br>NO-1753 Halden, Norway</p>
<p>Distributed by:<br>Merck Sharp &amp; Dohme Corp., a subsidiary of<br><span class="Bold">Merck &amp; Co, Inc.</span><br>Whitehouse Station, NJ 08889, USA </p>
<p>AVELOX<span class="Sup">Â®</span> is a registered trademark of Bayer Aktiengesellschaft and is used under license by Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co</span>., Inc.</p>
<p><span class="Bold">Rx Only</span></p>
<p>Â©2012 Bayer HealthCare Pharmaceuticals Inc.</p>
<p>83680831, R.3</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Avelox </p>
<p><br></p>
<p>GENERIC: moxifloxacin hydrochloride</p>
<p><br></p>
<p>DOSAGE: TABLET, FILM COATED</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 52125-525-57</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>MOXIFLOXACIN HYDROCHLORIDE 400mg in 1</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>CELLULOSE, MICROCRYSTALLINE</li>
<li>TITANIUM DIOXIDE</li>
<li>HYPROMELLOSES</li>
<li>POLYETHYLENE GLYCOLS</li>
<li>CROSCARMELLOSE SODIUM</li>
<li>LACTOSE MONOHYDRATE</li>
<li>FERRIC OXIDE RED</li>
<li>MAGNESIUM STEARATE</li>
</ul>
<p><br></p>
<p>COLOR: red</p>
<p><br></p>
<p>SHAPE: OVAL</p>
<p><br></p>
<p>SCORE: No score</p>
<p><br></p>
<p>SIZE: 17 mm</p>
<p><br></p>
<p>IMPRINT: BAYER;M400</p>
<p><br></p>
<p>PACKAGING: 5  in 1 VIAL</p>
<p><br></p>
<p><br></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebe94683-8fd8-4d99-aa13-46ce14dbcd62&amp;name=MM3.jpg"></p>
<p><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebe94683-8fd8-4d99-aa13-46ce14dbcd62&amp;name=MM4.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AVELOXÂ 		
					</strong><br><span class="contentTableReg">moxifloxacin hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-525(NDC:0085-1733)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MOXIFLOXACIN HYDROCHLORIDE</strong> (MOXIFLOXACIN) </td>
<td class="formItem">MOXIFLOXACIN</td>
<td class="formItem">400Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (TABLET, FILM COATED) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BAYER;M400</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-525-57</td>
<td class="formItem">5  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021085</td>
<td class="formItem">07/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b7c38d62-2b75-424e-a847-5464751efa5d</div>
<div>Set id: ebe94683-8fd8-4d99-aa13-46ce14dbcd62</div>
<div>Version: 1</div>
<div>Effective Time: 20130708</div>
</div>
</div>Â <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
